[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 638
11. Elghissassi I, Mikou A, Inrhaoun H, Ennouhi A, Gamra L, Errihani H: Metastatic basal cell carcinoma to the bone and bone marrow. Int J Dermatol; 2009 May;48(5):481-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma to the bone and bone marrow.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common carcinoma in the community, but the incidence of metastatic events is exceedingly low.
  • The few reported cases most often appear in regional nodes or the lungs, and patients usually exhibit multiple concurrent organs of spread at the time of diagnosis.
  • METHODS: We report a case of primary BCC located on the left forehead of a 48-year-old man, which metastasized exclusively to the bone and bone marrow, associated with hematologic disorders.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Bone Neoplasms / secondary. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416377.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Li N, Wolgamot G, Argenyi Z: Primary cutaneous neuroendocrine cell carcinoma (Merkel cell carcinoma) with prominent microcystic features, mimicking eccrine carcinoma. J Cutan Pathol; 2007 May;34(5):410-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous neuroendocrine cell carcinoma (Merkel cell carcinoma) with prominent microcystic features, mimicking eccrine carcinoma.
  • Although primary cutaneous neuroendocrine cell carcinoma [Merkel cell carcinoma (MCC)] may show divergent features, including microcystic ('tubuloglandular'), squamous, eccrine and rhabdomyoblastic, a diffuse microcystic pattern is exceedingly rare.
  • In this study, we present two cases of MCC with prominent microcystic features, which precluded a definitive diagnosis in the initial punch biopsy.
  • Punch biopsies from both patients revealed an infiltrating neoplasm with prominent microcystic features that mimick tubuloglandular structures, lined by hyperchromatic basaloid cells, which were strongly positive for chromogranin and BerEP4, variably positive for CK7 and CK5/6 and negative for CK20, synaptophysin, S-100, epithelial membrane antigen (EMA), gross cystic disease fluid protein-15 (GCDFP-15), estrogen/progesterone receptors (ER/PR), thyroid transcription factor 1 (TTF1) and carcinoembryonic antigen (CEA).
  • Although the lack of CK20 staining is unusual, the histologic characteristics along with the remaining immunohistochemical studies favor the diagnosis of a primary cutaneous neuroendocrine cell carcinoma over the variants of eccrine carcinoma or basal cell carcinoma with neuroendocrine differentiation.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Eccrine Glands / pathology. Humans. Immunohistochemistry. Male. Neck / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448197.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Green WH, Wang SQ, Cognetta AB Jr: Total-body cutaneous examination, total-body photography, and dermoscopy in the care of a patient with xeroderma pigmentosum and multiple melanomas. Arch Dermatol; 2009 Aug;145(8):910-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Xeroderma pigmentosum (XP) is an autosomal recessive disorder characterized by a defect in DNA repair and subsequent increased frequency of cutaneous malignant neoplasms, including melanoma.
  • In patients with XP, patient and family education and aggressive UV radiation protection are the primary means of skin cancer prevention.
  • OBSERVATIONS: We describe a 39-year-old woman with XP who developed 38 primary melanomas along with 6 squamous cell carcinomas and 70 basal cell carcinomas over a 23-year period.
  • The ratio of benign to malignant biopsied suspicious melanocytic lesions during 23 years of follow-up was 0.9:1.
  • All melanomas were treated using wide local excision, and she had no evidence of local or in-transit metastases of any of her malignant neoplasms at the most recent follow-up examination.
  • [MeSH-major] Dermoscopy. Melanoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Photography. Physical Examination. Skin Neoplasms / diagnosis. Xeroderma Pigmentosum / complications
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Female. Humans


1
Advertisement
4. Schmerber S, Righini Ch, Soriano E, Delalande C, Dumas G, Reyt E, Lavieille JP: [The outcome of treatments for carcinoma of the external auditory canal]. Rev Laryngol Otol Rhinol (Bord); 2005;126(3):165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The outcome of treatments for carcinoma of the external auditory canal].
  • OBJECTIVE: A retrospective analysis of management and survival of patients treated for temporal bone carcinoma.
  • PATIENTS AND METHODS: Thirty patients underwent treatment for carcinoma of the temporal bone.
  • Twenty-five squamous cell carcinomas, 1 melanoma, 2 basocellular carcinomas and 2 adenoid cystic carcinomas were treated.
  • Overall stages a complete remission was found in 65% and 23%, and deceased was 35% and 77%, respectively for the primary treatment group and the salvage surgery group.
  • CONCLUSION: Long-term prognosis of the carcinoma of the external auditory canal mainly depends on the stage and primary treatment.
  • The improved survival (65%) of patients treated de novo compared with those treated with salvage surgery (23%) suggests that early referral and aggressive primary surgical treatment with postoperative radiotherapy offer the greatest chance of cure.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Ear Canal. Ear Neoplasms / therapy. Ear, Middle. Melanoma / therapy. Skull Neoplasms / therapy. Temporal Bone
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Parotid Gland / surgery. Petrous Bone / surgery. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366384.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. MacGregor JL, Campanelli C, Friedman PC, Desciak E: Basal cell and squamous cell carcinoma occurring within a field of multiple tumors of the follicular infundibulum. Dermatol Surg; 2008 Nov;34(11):1567-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell and squamous cell carcinoma occurring within a field of multiple tumors of the follicular infundibulum.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Facial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology


16. Pivarcsi A, Müller A, Hippe A, Rieker J, van Lierop A, Steinhoff M, Seeliger S, Kubitza R, Pippirs U, Meller S, Gerber PA, Liersch R, Buenemann E, Sonkoly E, Wiesner U, Hoffmann TK, Schneider L, Piekorz R, Enderlein E, Reifenberger J, Rohr UP, Haas R, Boukamp P, Haase I, Nürnberg B, Ruzicka T, Zlotnik A, Homey B: Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A; 2007 Nov 27;104(48):19055-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The novel keratinocyte-specific chemokine CCL27 plays a critical role in the organization of skin-associated immune responses by regulating T cell homing under homeostatic and inflammatory conditions.
  • Here we demonstrate that human keratinocyte-derived skin tumors may evade T cell-mediated antitumor immune responses by down-regulating the expression of CCL27 through the activation of epidermal growth factor receptor (EGFR)-Ras-MAPK-signaling pathways.
  • Compared with healthy skin, CCL27 mRNA and protein expression was progressively lost in transformed keratinocytes of actinic keratoses and basal and squamous cell carcinomas.
  • In mice, neutralization of CCL27 led to decreased leukocyte recruitment to cutaneous tumor sites and significantly enhanced primary tumor growth.
  • [MeSH-major] Carcinoma, Basal Cell / immunology. Carcinoma, Squamous Cell / immunology. Chemokine CCL27 / physiology. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / physiology. Skin Neoplasms / immunology. Tumor Escape / physiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14470-5 [10588729.001]
  • [Cites] Cancer Gene Ther. 2006 Apr;13(4):393-405 [16224496.001]
  • [Cites] J Immunol. 2000 Apr 1;164(7):3465-70 [10725697.001]
  • [Cites] Annu Rev Immunol. 2000;18:217-42 [10837058.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1567-79 [11583982.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7552-5 [11606393.001]
  • [Cites] Nat Med. 2002 Feb;8(2):157-65 [11821900.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):477-85 [11900233.001]
  • [Cites] Nat Rev Immunol. 2002 Mar;2(3):175-84 [11913068.001]
  • [Cites] Recent Results Cancer Res. 2002;160:251-8 [12079221.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1189-96 [12133939.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:2-8 [12202782.001]
  • [Cites] Immunol Rev. 2002 Oct;188:97-113 [12445284.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):201-2 [12676577.001]
  • [Cites] J Virol. 2003 Jul;77(13):7393-400 [12805438.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4420-5 [12907614.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 23;317(1):68-76 [15047149.001]
  • [Cites] FEBS Lett. 2004 Jun 1;567(1):63-6 [15165894.001]
  • [Cites] J Immunol. 1989 May 15;142(10):3714-25 [2785562.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904 [2593166.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2840-7 [2183932.001]
  • [Cites] Cell. 1990 May 4;61(3):407-17 [2185890.001]
  • [Cites] Prog Clin Biol Res. 1992;376:61-84 [1528930.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):897-908 [9670968.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):447-58 [15542429.001]
  • [Cites] Oncologist. 2005 May;10(5):345-56 [15851793.001]
  • [Cites] FASEB J. 2005 Nov;19(13):1836-8 [16170018.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):573-8 [10662803.001]
  • (PMID = 18025475.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CCL27 protein, human; 0 / Ccl27 protein, mouse; 0 / Chemokine CCL27; 0 / Neoplasm Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2141907
  •  go-up   go-down


17. Martinsson H, Yhr M, Enerbäck C: Expression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiation. Exp Dermatol; 2005 Mar;14(3):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S100A7 and S100A9 have been shown to be markedly upregulated both in ductal carcinoma in situ of the breast and in psoriasis.
  • Using Western blot analysis and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), both S100A7 and S100A9 were shown to be induced in normal primary keratinocytes (HEKn), when differentiation was promoted by high extracellular calcium, loss of contact with extracellular matrix and confluent conditions, as previously reported for S100A7 in mammary epithelial cells.
  • They were both absent in undifferentiated basalioma and strongly expressed in carcinoma in situ, as well as in keratoacanthoma and differentiated squamous cell carcinoma.
  • In normal epithelium, they were expressed in the superficial, differentiated region of the epithelium rather than in the basal region.
  • [MeSH-minor] Blotting, Western. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation / physiology. Cell Line. Computer Systems. Humans. Immunohistochemistry. Keratoacanthoma / metabolism. Keratoacanthoma / pathology. Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction. S100 Proteins. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15740587.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Calgranulin B; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


18. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group: Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer; 2009 Jun 1;115(11):2523-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.
  • BACKGROUND: Actinic keratoses (AKs) are established as direct precursors of squamous cell carcinoma (SCC), but there is significant controversy regarding the rate at which AKs progress to SCC.
  • The authors of this report studied a high-risk population to estimate the risk of progression of AK to SCC and to basal cell carcinoma (BCC) and the risk of spontaneous regression of untreated AKs.
  • The risk of progression of AK to primary SCC (invasive or in situ) was 0.60% at 1 year and 2.57% at 4 years.
  • Approximately 65% of all primary SCCs and 36% of all primary BCCs diagnosed in the study cohort arose in lesions that previously were diagnosed clinically as AKs.
  • CONCLUSIONS: In the current study, the authors quantified the malignant potential of clinically diagnosed AKs for both SCC and BCC, although many did not persist, and the results suggested that AKs may play a greater role in the overall burden of keratinocyte carcinomas than previously documented.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Disease Progression. Keratosis, Actinic / pathology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382202.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01AR49342; United States / NCI NIH HHS / CA / R01CA106592; United States / NCI NIH HHS / CA / R01CA106807; United States / NCI NIH HHS / CA / R25CA087972
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Investigator] Weinstock MA; Marcolivio K; Weinstock M; Bingham S; DiGiovanna J; Hall R; Naylor M; Taylor JR; Vertrees J; White C; Hall R; Hannah D; Eilers D; Liang T; Sakla N; Kreuger A; Cole G; Jeffes E; Labrador T; Taylor JR; Kirsner R; Kerri JE; Falabela AG; Givens M; Naylor M; Benson MB; Perry L; Kalivas J; Yanni C; Targovnik S; Austin J; Collier S; Collins JF; Bingham S; Calvert B; Connor P; Crigler C; Davis D; Grubb P; Kelly J; Kirk G; Lawson K; Linzy L; Palmer L; Rhoads M; Sather M; Copeland E; Fye C; Gagne W; de Naranjo PG; Messick C; Vertrees J; Piepkorn M; White C; Lew R; Braverman I; Cole B; Kalish R; McLean D; Thiers B
  •  go-up   go-down


19. Green AC, McBride P: Squamous cell carcinoma of the skin (non-metastatic). BMJ Clin Evid; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the skin (non-metastatic).
  • INTRODUCTION: Cutaneous squamous cell carcinoma is a malignant tumour of keratinocytes arising in the epidermis, with histological evidence of dermal invasion.
  • People with fair skin colour who sunburn easily without tanning, people with xeroderma pigmentosum, and people who are immunosuppressed are most susceptible to squamous cell carcinoma.
  • METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: Does the use of sunscreen help prevent cutaneous squamous cell carcinoma and solar keratosis?
  • What is the optimal margin for primary excision of cutaneous squamous cell carcinoma (non-metastatic)?
  • Does micrographically controlled surgery result in lower rates of local recurrence than standard primary excision in people with squamous cell carcinoma of the skin (non-metastatic)?
  • Does radiotherapy after surgery affect local recurrence of cutaneous squamous cell carcinoma in people with squamous cell carcinoma of the skin (non-metastatic)?
  • CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: micrographically controlled surgery, primary excision, radiotherapy after surgery, and sunscreens.
  • [MeSH-major] Carcinoma, Basal Cell. Neoplasm Recurrence, Local
  • [MeSH-minor] Carcinoma, Squamous Cell / epidemiology. Humans. Skin Neoplasms / epidemiology. Sunscreening Agents / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cutan Med Surg. 2003 Jul-Aug;7(4):300-5 [12879331.001]
  • [Cites] Surg Gynecol Obstet. 1966 Feb;122(2):245-8 [5901291.001]
  • [Cites] Arch Surg. 1974 Jan;108(1):50-1 [4808574.001]
  • [Cites] Cancer. 1989 May 1;63(9):1863-71 [2702595.001]
  • [Cites] Am J Clin Oncol. 1991 Oct;14(5):383-6 [1951174.001]
  • [Cites] J Am Acad Dermatol. 1992 Mar;26(3 Pt 2):467-84 [1564155.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):574-7 [1463102.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):512-8 [8504041.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] Arch Dermatol. 1994 Aug;130(8):1018-21 [8053698.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Nov;113(5):589-96 [7478649.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):89-93 [10758309.001]
  • [Cites] Aust N Z J Surg. 2000 May;70(5):358-61 [10830600.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1061-9 [11240248.001]
  • [Cites] Arch Dermatol. 2003 Apr;139(4):451-5 [12707092.001]
  • [Cites] Plast Reconstr Surg. 2003 Jul;112(1):57-63 [12832877.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):124-30 [8606543.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1034-40 [8942434.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):628-34 [9610717.001]
  • [Cites] J Am Acad Dermatol. 1998 Jun;38(6 Pt 1):960-6 [9632005.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1304-9 [10433619.001]
  • [Cites] Head Neck. 1999 Sep;21(6):526-30 [10449668.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Med J Aust. 2006 Jan 2;184(1):6-10 [16398622.001]
  • [Cites] Prev Med. 2006 Mar;42(3):171-6 [16325898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2546-8 [17132769.001]
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1301-7 [17535230.001]
  • [Cites] Int Arch Occup Environ Health. 2009 Feb;82(3):357-63 [18649084.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2009 Apr;62(4):457-61 [18218349.001]
  • (PMID = 21733203.001).
  • [ISSN] 1752-8526
  • [Journal-full-title] BMJ clinical evidence
  • [ISO-abbreviation] BMJ Clin Evid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sunscreening Agents
  • [Other-IDs] NLM/ PMC2907617
  •  go-up   go-down


20. Heal C, Buettner P, Browning S: Risk factors for wound infection after minor surgery in general practice. Med J Aust; 2006 Sep 4;185(5):255-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SETTING: Primary care in a regional centre, Queensland, October 2004 to May 2005.
  • Excisions from lower legs and feet (P = 0.009) or thighs (P = 0.005), excisions of basal cell carcinoma (P = 0.006) or squamous cell carcinoma (P = 0.002), and diabetes (P < 0.001) were independent risk factors for wound infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948620.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


21. Papadopoulos O, Kostopoulos E, Karypidis D, Tsantoulas Z, Moustaki M: Review of nasal reconstruction. J Craniofac Surg; 2009 Jul;20(4):1072-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were analyzed in relation to their age, sex, location of the defect, histologic diagnosis of the lesion, type of reconstruction, recurrence of the tumor, and final outcome.
  • Basal cell carcinoma was the most common type, affecting 1399 patients (87.8%), followed by squamous cell carcinoma, which was identified in 109 patients (6.8%).
  • Cutaneous melanoma was not a frequent diagnosis.
  • Excision and primary closure represented the most frequent type of reconstruction, followed by flap reconstruction and any type of graft.
  • Efficient diagnosis and appropriate reconstruction are prerequisites for the final desired outcome.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506524.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gaudet JE, Walvekar RR, Arriaga MA, Dileo MD, Nuss DW, Pou AM, Hagan J, Lin J: Applicability of the pittsburgh staging system for advanced cutaneous malignancy of the temporal bone. Skull Base; 2010 Nov;20(6):409-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives are to evaluate the applicability of the Pittsburgh staging system (PSS) (designed for primary temporal bone malignancies) to advanced periauricular cutaneous malignancies with temporal bone involvement and to study treatment outcomes and prognostic factors predicting recurrence-free survival.
  • Patients with primary temporal bone or parotid gland malignancies were excluded.
  • Patients with basal cell carcinoma were managed with wide local excision and lateral temporal bone resection (WLE/LTBR) without adjuvant therapy.
  • Treatment for squamous cell carcinoma patients involved multimodality therapy.
  • Basal cell carcinoma was well controlled with WLE/LTBR alone without adjuvant therapy, whereas squamous cell carcinoma required multimodality therapy: WLE/LTBR and postoperative radiation with or without chemotherapy.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 1999 Jul;121(1):62-5 [10388880.001]
  • [Cites] Am J Otol. 2000 Jul;21(4):582-8 [10912706.001]
  • [Cites] J Laryngol Otol. 2001 Feb;115(2):85-6 [11320842.001]
  • [Cites] Dermatol Surg. 2005 Nov;31(11 Pt 1):1379-84 [16416604.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2008 Oct;61(10):1140-7 [18675609.001]
  • [Cites] J Laryngol Otol. 1993 Aug;107(8):697-702 [8409719.001]
  • [Cites] Otolaryngol Clin North Am. 1993 Apr;26(2):231-45 [8460040.001]
  • [Cites] Laryngoscope. 1990 Oct;100(10 Pt 1):1047-51 [2215034.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Sep;99(9 Pt 1):714-21 [2396807.001]
  • [Cites] Laryngoscope. 1987 Feb;97(2):158-64 [3807618.001]
  • [Cites] Laryngoscope. 1983 Jan;93(1):87-105 [6337311.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Mar;110(3):270-80 [8134137.001]
  • (PMID = 21772797.001).
  • [ISSN] 1532-0065
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3134817
  • [Keywords] NOTNLM ; Pittsburgh staging system / periauricular cutaneous malignancy / temporal bone
  •  go-up   go-down


23. Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM: Bladder cancer stem cells. Curr Stem Cell Res Ther; 2010 Dec;5(4):387-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem cells are undifferentiated cells that renew themselves while simultaneously producing differentiated tissue- or organspecific cells through asymmetric cell division.
  • The appreciation of the importance of stem cells in normal tissue biology has prompted the idea that cancers may also develop from a progenitor pool (the "cancer stem cell (CSC) hypothesis"), and this idea is gaining increasing acceptance among scientists.
  • Recently, the tissue-specific stem cells of the normal urothelium have been proposed to reside in the basal layer, and investigators have isolated phenotypically similar populations of cells from urothelial cancer cell lines and primary tumors.
  • Herein, we review the CSC hypothesis and apply it to explain the development of the two different types of bladder cancer: noninvasive ("superficial") carcinoma and invasive carcinoma.
  • [MeSH-major] Carcinoma / pathology. Neoplastic Stem Cells / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Disease Progression. Humans. Models, Biological. Neoplasm Invasiveness. Organ Specificity. Stem Cell Niche

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20955163.001).
  • [ISSN] 2212-3946
  • [Journal-full-title] Current stem cell research & therapy
  • [ISO-abbreviation] Curr Stem Cell Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Stokman MA, Spijkervet FK, Burlage FR, Roodenburg JL: Clinical effects of flurbiprofen tooth patch on radiation-induced oral mucositis. A pilot study. Support Care Cancer; 2005 Jan;13(1):42-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the development of mucositis several mechanisms play a role, such as inflammation and the effect of radiation on the high proliferation rate of oral basal epithelial cells.
  • Therefore, administration of a drug with antiinflammatory and antiproliferative properties might delay the disorder and/or alleviate the severity of oral mucositis.
  • METHODS: The study group comprised 12 patients with a malignant tumor in the head and neck region to be treated with primary curative or postoperative radiotherapy.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / radiotherapy. Female. Head and Neck Neoplasms / radiotherapy. Humans. Male. Middle Aged. Pilot Projects

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatology. 1997;195 Suppl 2:57-61 [9403257.001]
  • [Cites] Cancer. 2004 May 1;100(9 Suppl):2026-46 [15108223.001]
  • [Cites] Crit Rev Oral Biol Med. 2003;14(3):213-25 [12799324.001]
  • [Cites] Strahlenther Onkol. 1999 Feb;175(2):74-7 [10065142.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):253-62 [12742264.001]
  • [Cites] J Oral Pathol Med. 2002 Mar;31(3):153-7 [11903821.001]
  • [Cites] Arch Otolaryngol. 1982 Jan;108(1):21-4 [7053744.001]
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):275-9 [9069297.001]
  • [Cites] J Oral Pathol Med. 1989 Mar;18(3):167-71 [2760855.001]
  • [Cites] Ann Oncol. 1998 May;9(5):505-9 [9653491.001]
  • [Cites] Inflamm Res. 1998 Oct;47 Suppl 2:S78-87 [9831328.001]
  • [Cites] Conn Med. 1989 Oct;53(10):595-601 [2582763.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):277-84 [15057287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):917-30 [11240232.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):875-85 [11550161.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):170-6 [14693241.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1012-6 [12671696.001]
  • [Cites] Strahlenther Onkol. 1998 Nov;174 Suppl 3:4-7 [9830447.001]
  • [Cites] J Rheumatol. 1992 Jun;19(6):921-6 [1404130.001]
  • [Cites] Am J Ther. 2003 May-Jun;10(3):170-5 [12756424.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):479-85 [12243825.001]
  • [Cites] Br J Oral Maxillofac Surg. 1990 Apr;28(2):89-91 [2337569.001]
  • [Cites] Cancer. 1999 May 15;85(10):2103-13 [10326686.001]
  • (PMID = 15365799.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 5GRO578KLP / Flurbiprofen
  •  go-up   go-down


25. Firat Y, Kizilay A, Akarcay M, Miman MC: Second primary cancer occurrence on forehead flap after reconstruction of nasal carcinoma. J Craniofac Surg; 2008 Nov;19(6):1549-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary cancer occurrence on forehead flap after reconstruction of nasal carcinoma.
  • We reported a case of basal cell carcinoma on the flap which was initially treated with excision of squamous cell carcinoma and forehead flap reconstruction of nasal dorsum.
  • After 8 years of reconstruction, basal cell carcinoma was developed on the flap surface.
  • This may be due to a recurrence, or a second primary tumor, or an activation of a dormant tumor with perturbing factors like surgery.
  • In this report, our purpose was to discuss the possible etiopathogenesis, most appropriate diagnostic procedures, and treatment protocol for a carcinoma of the flap which has been used to reconstruct the previous cutaneous cancer.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / surgery. Forehead / pathology. Neoplasms, Second Primary / pathology. Nose Neoplasms / surgery. Skin Neoplasms / pathology. Surgical Flaps / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098548.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Akrish S, Peled M, Ben-Izhak O, Nagler RM: Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis. Oral Oncol; 2009 Dec;45(12):1044-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis.
  • The classification system for malignant salivary gland tumors (MST) is largely dependent on its histogenesis.
  • The histogenesis is uncertain but the "bicellular theory of origin" has been accepted by most and states that malignant transformation of reserve cells from either the intercalated or excretory duct are responsible for the development of MST.
  • Fifty six primary major and minor gland MST were stained with anti-cox-2 antibody and rated with a combined score that added a scale of intensity to the percentage of tumor cells that overexpressed the cox-2 protein.
  • Strong cox-2 overexpression was noted in all MST of proposed excretory duct origin: salivary duct carcinoma (100%), mucoepidermoid carcinoma (MEC) (92%), and adenocarcinoma nos (AdC nos) (83%).
  • Primary squamous cell carcinoma (PSCC) was the exception.
  • Negative expression was noted in all tumors of proposed intercalated duct origin (adenoid cystic carcinoma, basal cell adenocarcinoma and acinic cell carcinoma) with the exception of one case of polymorphous low grade adenocarcinoma.
  • Strong cox-2 overexpression was noted in the epidermoid cells of MEC, abluminal duct cells surrounding the duct-like structures and ductal cells of AdC nos and salivary duct carcinoma.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729335.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


27. Carneiro BA, Watkin WG, Mehta UK, Brockstein BE: Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest; 2006 Jun-Jul;24(4):396-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia.
  • Basal cell carcinoma (BCC) is usually a benign and indolent cancer cured in greater than 95 percent of cases.
  • We report a case of BCC metastatic to the lungs, occurring 17 years after the primary BCC was noticed, that responded to carboplatin and paclitaxel on 3 occasions.
  • The patient also developed pure red cell aplasia (PRCA).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Basal Cell / secondary. Lung Neoplasms / secondary. Paraneoplastic Syndromes / complications. Red-Cell Aplasia, Pure / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16777692.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


28. Byrne CM, Thompson JF: Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Rev Anticancer Ther; 2006 May;6(5):671-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors.
  • It is potentially useful for treating patients with metastatic tumors, such as melanoma, and even select primary tumors, such as head and neck squamous cell carcinomas and basal cell carcinoma.
  • Particular focus is placed on trials involving melanoma, head and neck cancers and other primary and metastatic skin cancers.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16759159.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 11116-32-8 / bleomycetin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 69
  •  go-up   go-down


29. Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I, Szijan I: Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol Med; 2010 Jul-Aug;16(7-8):262-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Hedgehog (Hh) signaling pathway has an important role during embryogenesis and in adult life, regulating proliferation, angiogenesis, matrix remodeling and stem-cell renewal.
  • Deregulation of the Hh pathway is involved in tumor development, since mutations in several components of this pathway were found in patients with basal cell carcinoma, medulloblastoma and other tumors; however, the role of Hh in meningiomas has not been studied yet.
  • Meningiomas represent 30% of primary cranial tumors, are mostly benign and prevail in the second half of life.
  • To provide information concerning molecular alterations, by use of real-time RT-PCR, we studied expression at the mRNA level of 32 Hh pathway and target genes in 36 meningioma specimens of different grades. mRNA levels of 16 genes, involved mainly in Hh pathway activation and cell proliferation, increased in meningiomas in comparison with normal tissue, whereas those of 7 genes, mainly related to Hh pathway repression, decreased.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2004 May;122(5):1180-7 [15140221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cytogenet Cell Genet. 1996;72(4):297-8 [8641133.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):143-51 [15736317.001]
  • [Cites] Development. 2005 Dec;132(23):5249-60 [16284117.001]
  • [Cites] Cancer Biol Ther. 2005 Oct;4(10):1050-4 [16258256.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):33-8 [16371461.001]
  • [Cites] Dev Biol. 2006 Feb 1;290(1):1-12 [16364285.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1334-40 [16501253.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):159-65 [17303409.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):943-54 [17410535.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] BMC Dev Biol. 2007;7:111 [17925019.001]
  • [Cites] Curr Biol. 2008 Mar 25;18(6):R238-41 [18364223.001]
  • [Cites] Curr Oncol Rep. 2008 Mar;10(2):107-13 [18377823.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2707-18 [18381746.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):692-7 [18477794.001]
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):438-49 [18500245.001]
  • [Cites] J Biol Chem. 2008 Jul 25;283(30):20770-8 [18524773.001]
  • [Cites] Genes Dev. 2008 Sep 15;22(18):2454-72 [18794343.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8788-95 [18974121.001]
  • [Cites] Development. 2009 Mar;136(6):1029-38 [19234065.001]
  • [Cites] J Biol Chem. 2009 Aug 21;284(34):22888-97 [19556240.001]
  • [Cites] Neurobiol Dis. 2004 Apr;15(3):483-91 [15056455.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):758-65 [12866037.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:47-65 [12142354.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30901-13 [12042312.001]
  • [Cites] Nature. 2002 May 16;417(6886):299-304 [12015606.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10139-49 [11741991.001]
  • [Cites] Dev Biol. 2001 Aug 1;236(1):30-45 [11456442.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] N Engl J Med. 2009 Nov 19;361(21):2094-6 [19923581.001]
  • (PMID = 20386868.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hedgehog Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2896461
  •  go-up   go-down


30. Brozova M, Kleibl Z, Netikova I, Sevcik J, Scholzova E, Brezinova J, Chaloupkova A, Vesely P, Dundr P, Zadinova M, Krasna L, Matouskova E: Establishment, growth and in vivo differentiation of a new clonal human cell line, EM-G3, derived from breast cancer progenitors. Breast Cancer Res Treat; 2007 Jun;103(2):247-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment, growth and in vivo differentiation of a new clonal human cell line, EM-G3, derived from breast cancer progenitors.
  • A new clonal cell line, EM-G3, was derived from a primary lesion of human infiltrating ductal breast carcinoma.
  • The line consisted of cuboidal cells with occasional appearance of more differentiated branched cells apparently involved in cell-to-cell communication.
  • Detection of integrins alpha-6, beta-1, and protein CD44 by cDNA array also pointed to the character of basal/stem cells.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Differentiation. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Karyotyping. Mice. Mice, Nude. Mutation. Oligonucleotide Array Sequence Analysis


31. Li JH, Xing X, Li P, Xu J: Transposition movement of V-Y flaps for facial reconstruction. J Plast Reconstr Aesthet Surg; 2007;60(11):1244-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meanwhile, the flap allowed for a primary closure of the defects along the nasolabial fold or preauricular crease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Patient Satisfaction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950187.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


32. Rosendahl AH, Forsberg G: IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells. Kidney Int; 2006 Nov;70(9):1584-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells.
  • Renal cell carcinoma (RCC) is the most prevalent cancer of the kidney.
  • In this study, the analysis was expanded to include the interaction between the IGF and transforming growth factor-beta (TGF-beta) systems in the human RCC cells Caki-2 (from a primary tumor) and SK-RC-52 (from a metastasis).
  • Functional effects such as cell proliferation, TGF-beta receptor (TbetaR) signaling, and IGFBP-3 levels were monitored after stimulation with various concentrations of IGF-I, TGF-beta, and IGFBP-3.
  • TGF-beta regulated the endogenous IGFBP-3 levels in these RCC cells as neutralizing anti-TGF-beta(1-3) antibodies strongly reduced the basal IGFBP-3 level.
  • This study demonstrates a direct interaction of the IGF and TGF-beta systems in human renal carcinoma cells.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Insulin-Like Growth Factor Binding Protein 3 / physiology. Insulin-Like Growth Factor I / physiology. Kidney Neoplasms / metabolism. Transforming Growth Factor beta / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Gene Expression Regulation, Neoplastic. Humans. Mice. Receptor Cross-Talk / physiology. Receptors, Transforming Growth Factor beta / physiology. Signal Transduction / physiology. Smad2 Protein / genetics. Smad2 Protein / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969385.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Receptors, Transforming Growth Factor beta; 0 / SMAD2 protein, human; 0 / Smad2 Protein; 0 / Transforming Growth Factor beta; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


33. Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D: Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol; 2010 Jan;162(1):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Background Patients with a previous medical history of nonmelanoma skin cancers (NMSCs) often develop multiple or recurrent malignant lesions around the site of the primary tumour.
  • This finding led to the field cancerization theory, which suggests that the entire epithelial surface of the regional skin has an increased risk for the development of malignant lesions.
  • [MeSH-major] Facial Neoplasms / prevention & control. Head and Neck Neoplasms / drug therapy. Neoplasms, Second Primary / prevention & control. Photochemotherapy. Scalp. Skin Neoplasms / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Keratosis, Actinic / drug therapy. Male. Middle Aged. Photosensitizing Agents / therapeutic use


34. Jellinek NJ: Primary malignant tumors of the nail unit. Adv Dermatol; 2005;21:33-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant tumors of the nail unit.
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / surgery. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Humans. Melanoma / diagnosis. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16350437.001).
  • [ISSN] 0882-0880
  • [Journal-full-title] Advances in dermatology
  • [ISO-abbreviation] Adv Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 134
  •  go-up   go-down


35. Franchi A, Massi D, Gallo O, Santucci M, Porfirio B: Radiation-induced cutaneous carcinoma of the head and neck: is there an early role for p53 mutations? Clin Exp Dermatol; 2006 Nov;31(6):793-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced cutaneous carcinoma of the head and neck: is there an early role for p53 mutations?
  • METHODS: The study group comprised six patients affected by cutaneous carcinomas arising in radiodermatitis (one squamous cell carcinoma and five basal cell carcinomas), and seven patients presenting only chronic radiodermatitis.
  • [MeSH-minor] Base Sequence. DNA, Neoplasm / genetics. Genetic Predisposition to Disease. Humans. Immunoenzyme Techniques. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / genetics. Neoplasms, Second Primary / metabolism. Polymorphism, Single-Stranded Conformational. Radiodermatitis / genetics. Radiodermatitis / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824052.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


36. Eggers G, Flechtenmacher C, Kurzen H, Hassfeld S: Infiltrating basal cell carcinoma of the neck 34 years after irradiation of an haemangioma in early childhood. A case-report. J Craniomaxillofac Surg; 2005 Jun;33(3):197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating basal cell carcinoma of the neck 34 years after irradiation of an haemangioma in early childhood. A case-report.
  • A case of a 34-year-old Caucasian male is presented with a basal cell carcinoma deeply infiltrating the structures of the neck, including skeletal muscles and reaching the parotid gland.
  • The effects of this treatment when given in childhood in the aetiology of a basal cell carcinoma are discussed.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Head and Neck Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878521.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


37. Tuncer S, Kuvat SV, Kabakas F, Ermis I: Expansion of skin by a lipoma and its use as a full-thickness skin graft. Plast Reconstr Surg; 2006 Mar;117(3):1058-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Lipoma / surgery. Neoplasms, Multiple Primary / surgery. Scalp. Skin Neoplasms / surgery. Skin Transplantation

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525329.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


38. de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E: Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer; 2010 Oct 12;103(8):1192-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to establish and characterise a new human breast carcinoma xenograft obtained from a woman carrying a germline BRCA2 mutation.
  • RESULTS: Histological profile identified the tumour as a basal-like triple-negative breast cancer.
  • Comparative genomic hybridisation array profiles of the primary tumour and the xenograft revealed a high number of similar genetic alterations.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Genes, BRCA2. Germ-Line Mutation
  • [MeSH-minor] Adult. Animals. Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Culture Techniques. Cell Line, Tumor. Comparative Genomic Hybridization. DNA Mutational Analysis. Female. Heterozygote. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Transplantation, Heterologous. Xenograft Model Antitumor Assays / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3989-98 [17606733.001]
  • [Cites] Breast Cancer Res. 2007;9(2):R24 [17417968.001]
  • [Cites] Nature. 2008 Feb 28;451(7182):1111-5 [18264088.001]
  • [Cites] Pathobiology. 2008;75(2):85-94 [18544963.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10021-3 [19074863.001]
  • [Cites] N Engl J Med. 2009 Jul 9;361(2):123-34 [19553641.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):432-42 [10862052.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2310-8 [11981002.001]
  • [Cites] Hum Mutat. 2002 Sep;20(3):218-26 [12203994.001]
  • [Cites] Hum Mutat. 2004 Apr;23(4):379-84 [15024732.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):489-95 [15369450.001]
  • [Cites] Nat Genet. 1992 Oct;2(2):128-31 [1303261.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1673-5 [7731724.001]
  • [Cites] Nat Genet. 1999 May;22(1):10 [10319850.001]
  • [Cites] Nat Genet. 1999 May;22(1):37-43 [10319859.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):230-6 [15540206.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):913-7 [15829966.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7612-21 [16140926.001]
  • [Cites] Fam Cancer. 2006;5(2):135-42 [16736282.001]
  • [Cites] Bioinformatics. 2006 Sep 1;22(17):2066-73 [16820431.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2182-92 [16985051.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5885-97 [16998503.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):311-7 [16609945.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):867-76 [17307353.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1329-33 [17416853.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2728-37 [17473206.001]
  • [Cites] Semin Oncol. 2007 Oct;34(5):384-91 [17920892.001]
  • (PMID = 20877358.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines
  • [Other-IDs] NLM/ PMC2967069
  •  go-up   go-down


39. Berking C: [Photocarcinogenesis. Molecular mechanisms and preventive strategies]. Hautarzt; 2007 May;58(5):398-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to avoid malignant transformation, various protective mechanisms have developed in the skin, whereby p53 plays a central role.
  • Chemoprevention has gained increasing importance for primary prevention.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Cell Transformation, Neoplastic / genetics. Neoplasms, Radiation-Induced / genetics. Skin Neoplasms / genetics. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Dermatol. 2006 Sep;15(9):678-84 [16881964.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):153-73 [15748645.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):933-46; quiz 947-50 [16713450.001]
  • [Cites] Dermatol Surg. 2006 Apr;32(4):562-8 [16681667.001]
  • [Cites] J Am Acad Dermatol. 2006 Jul;55(1):1-19 [16781287.001]
  • [Cites] Hautarzt. 2005 Jul;56(7):687-96; quiz 697 [15968560.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):91-106 [15748641.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2001 Nov-Dec;14(6):401-7 [11598440.001]
  • (PMID = 17429584.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 9
  •  go-up   go-down


40. Rozenchan PB, Carraro DM, Brentani H, de Carvalho Mota LD, Bastos EP, e Ferreira EN, Torres CH, Katayama ML, Roela RA, Lyra EC, Soares FA, Folgueira MA, Góes JC, Brentani MM: Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts. Int J Cancer; 2009 Dec 15;125(12):2767-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts.
  • To identify genes that were regulated by these reciprocal interactions, we cocultured a nonmalignant (MCF10A) and a breast cancer derived (MDA-MB231) basal cell lines, with fibroblasts isolated from breast benign-disease adjacent tissues (NAF) or with carcinoma-associated fibroblasts (CAF), in a transwell system.
  • In MDA-MB231 highly represented genes downregulated by CAF derived factors coded for proteins important for the specificity of vectorial transport between ER and golgi, possibly affecting cell polarity whereas the response of MCF10A comprised an induction of genes coding for stress responsive proteins, representing a prosurvival effect.
  • CAFs responded to the presence of both epithelial cells inducing genes implicated in cell proliferation.
  • Our data indicate that interactions between breast fibroblasts and basal epithelial cells resulted in alterations in the genomic profiles of both cell types which may help to clarify some aspects of this heterotypic signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Epithelial Cells / metabolism. Fibroblasts / metabolism. Gene Expression Profiling. Neoplasm Proteins / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Breast / cytology. Cell Proliferation. Coculture Techniques. Female. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 UICC.
  • (PMID = 19530251.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


41. Dong P, Li X, Zhu Z, Yu Z, Lu G, Sun Z, Wang S: [Expression of S-100 positive dendritic cell, TIMP-1 and p63 and its significance in the primary laryngeal carcinoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Feb;19(3):127-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of S-100 positive dendritic cell, TIMP-1 and p63 and its significance in the primary laryngeal carcinoma].
  • OBJECTIVE: To evaluate the predictive role of S-100 positive dendritic cell, tissue inhibitor of metalloproteinases-1 (TIMP-1) and p63 gene in primary laryngeal carcinoma with epidemiology (smoking and drinking), histological grading, surgical treatment, TNM stage and prognosis by the tissuechip technology.
  • METHODS: We studied the expression of dendritic cell (S-100), TIMP-1 and p63 gene on a series of 85 primary laryngeal carcinoma patients who had ever received in our hospital between 1992 and 2000 by the tissuechip technology and SP method.
  • In available 79 patients, the rate of expressing S-100 positive dendritic cell is 59.5% (47/79), and the average percentage of its labeled cells in them is 8.71%.
  • The rate is 55.7% (44/79) of the specimens whose basal membrane and extracellular matrix was strongly stained by TIMP-1; There was statistical significant in TIMP-1 protein demonstration between early and late stages, lymph node metastasis and 3-year survival rate ( P < 0.05) by chi-square test, but no relation with smoking, drinking, gender, age and histological classes (P > 0.05).
  • And the present study suggests TIMP-1 and S-100 could be the clinical discriminators in laryngeal carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844615.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / S100 Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


42. Fayter D, Corbett M, Heirs M, Fox D, Eastwood A: A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess; 2010 Jul;14(37):1-288
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PDT is used either as a primary treatment or as an adjunctive treatment.
  • PARTICIPANTS: People with Barrett's oesophagus, pre-cancerous skin conditions or primary cancer in the following sites: biliary tract, brain, head and neck, lung, oesophageal and skin.
  • For basal cell carcinoma (BCC), PDT may result in similar lesion response rates to surgery or cryotherapy but with better cosmetic outcomes.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • PubMed Health. PubMed Health .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663420.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  •  go-up   go-down


43. Makkonen KM, Malinen M, Ropponen A, Väisänen S, Carlberg C: Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene. J Mol Biol; 2009 Oct 23;393(2):261-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene.
  • The histone deacetylases 1, 5, 6, 7 and 11 are involved in the basal expression of Cyclin C, but in HEK293 and MCF-7 human breast carcinoma cells the antiproliferative effects of the histone deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) are not mediated by Cyclin C.
  • However, cell cycle progressing effects of all-trans RA and Forskolin are dependent on Cyclin C expression levels.
  • This suggests that the primary regulation of Cyclin C by all-trans RA and Forskolin mediates some of the cell cycle control actions of these compounds.
  • [MeSH-major] Cell Cycle / genetics. Colforsin / pharmacology. Cyclins / physiology. Tretinoin / pharmacology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Cell Line. Cell Line, Tumor. Chromatin Immunoprecipitation. Cyclic AMP Response Element-Binding Protein / genetics. Cyclic AMP Response Element-Binding Protein / metabolism. Cyclin C. Histone Deacetylase Inhibitors. Histone Deacetylases / physiology. Humans. Hydroxamic Acids / pharmacology. Nuclear Proteins / genetics. Nuclear Proteins / physiology. Nuclear Receptor Co-Repressor 1. Polymerase Chain Reaction. Promoter Regions, Genetic / genetics. Promoter Regions, Genetic / physiology. RNA, Small Interfering. Receptors, Retinoic Acid / metabolism. Repressor Proteins / genetics. Repressor Proteins / physiology

  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19683536.001).
  • [ISSN] 1089-8638
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CCNC protein, human; 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Cyclin C; 0 / Cyclins; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / NCOR1 protein, human; 0 / Nuclear Proteins; 0 / Nuclear Receptor Co-Repressor 1; 0 / RNA, Small Interfering; 0 / Receptors, Retinoic Acid; 0 / Repressor Proteins; 0 / retinoic acid receptor gamma; 1F7A44V6OU / Colforsin; 5688UTC01R / Tretinoin; 58IFB293JI / vorinostat; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


44. Wesley NO, Yu SS, Grekin RC, Neuhaus IM: Primary linear closure for large defects of the nasal supratip. Dermatol Surg; 2008 Mar;34(3):380-4; discussion 384-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary linear closure for large defects of the nasal supratip.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose / surgery. Nose Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2008 Oct;34(10):1439; author reply 1439-40 [18657159.001]
  • (PMID = 18190547.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Moskalik K, Kozlow A, Demin E, Boiko E: Powerful neodymium laser radiation for the treatment of facial carcinoma: 5 year follow-up data. Eur J Dermatol; 2010 Nov-Dec;20(6):738-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Powerful neodymium laser radiation for the treatment of facial carcinoma: 5 year follow-up data.
  • A retrospective non-comparative follow-up study was performed to evaluate the curative efficacy of powerful neodymium laser radiation (λ = 1,060 nm) for the treatment of 2,837 patients with 3,001 histologically confirmed facial skin carcinoma lesions of stages T1-2N0M0: 2,743 primary basal cell carcinomas (BCC), 172 recurrent limited basal cell carcinomas (RLBCC), and 86 primary squamous cells carcinomas (SCC).
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Laser Therapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neodymium. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21056940.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 2I87U3734A / Neodymium
  •  go-up   go-down


46. Janisson-Dargaud D, Durlach A, Lorenzato M, Grange F, Bernard P, Birembaut P: Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma. J Cutan Pathol; 2008 Oct;35(10):916-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC), the most common skin cancer, has an overall excellent prognosis, but recurrences are frequent.
  • METHODS: In order to evaluate the prognostic value of Epidermal Growth Factor Receptor (EGFR) expression, Ki-67 antigen expression and DNA ploidy, we compared primary tumors in 20 patients who had subsequent local recurrences and 20 matched controls without recurrences.
  • In contrast, we found that 78% of primary BCC in patients who experienced recurrences vs. 32% in the control group were aneuploid (p = 0.005).
  • [MeSH-major] Aneuploidy. Carcinoma, Basal Cell / genetics. Ki-67 Antigen / biosynthesis. Neoplasm Recurrence, Local / genetics. Receptor, Epidermal Growth Factor / biosynthesis. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2009 Jun;36(6):713-4 [19515054.001]
  • (PMID = 18537864.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


47. Røtterud R, Nesland JM, Berner A, Fosså SD: Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int; 2005 Jun;95(9):1344-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the epidermal growth factor receptor family in normal and malignant urothelium.
  • OBJECTIVE: To compare the immunohistochemically assessed expression of the epidermal growth factor receptor (EGFR) family in normal and malignant bladder urothelium, and suggest new hypotheses about their function in the development and progression of transitional cell carcinoma (TCC).
  • PATIENTS AND METHODS: EGFR, ERBB2, ERBB3 and ERBB4 were evaluated immunohistochemically in normal urothelium (NU, 15), primary non-metastasized invasive TCC (NMC, 19) and in primary invasive TCCs with corresponding metastases (MC, 51, both specimens).
  • RESULTS: All NU samples expressed ERBB4, none expressed ERBB2 and two expressed EGFR; all staining was uniform throughout all cell layers.
  • A current hypothesis, that superficial layers of NU do not express EGFR and thus protect the basal cells from the mitogenic effect of urinary EGF, is challenged.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Receptor, Epidermal Growth Factor / metabolism. Urinary Bladder / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. Neoplasm Metastasis. Urothelium / metabolism


48. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, Chan EK: CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther; 2010 Oct 1;10(7):694-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CIP2A expression and localization in oral carcinoma and dysplasia.
  • AIMS: Oral squamous cell carcinoma (OSCC) is the most prevalent malignancy of the oral cavity resulting in severe morbidity and mortality.
  • Cancerous inhibitor of PP2A (CIP2A) is a protein expressed in epithelial tissues that stabilizes the oncogene c-Myc and causes cell transformation.
  • This study was designed to investigate the expression of CIP2A in OSCC cell lines and tissues representing human normal, dysplasia and OSCC.
  • METHODS: Using quantitative real time PCR, mRNA quantification for CIP2A was performed in a primary gingival cell line and OSCCs CAL 27 and SCC-25.
  • RESULTS: CIP2A was significantly increased in the human carcinoma cell lines compared to the primary gingival cell line.
  • CIP2A was also preferentially localized in the dysplastic and OSCC epithelial areas compared to EGFR that was expressed mainly in areas of relatively normal epithelium and in dysplastic tissues above the basal layers.
  • CONCLUSIONS: CIP2A may play a significant role in oral malignant transformation and therefore, it may be a potential target for chemotherapy of OSCC.

  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Jul 25;21(32):5006-15 [12118381.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Mar;109(3):325-6 [20219595.001]
  • [Cites] J Oral Pathol Med. 2004 Feb;33(2):65-70 [14720191.001]
  • [Cites] Otolaryngol Clin North Am. 2006 Apr;39(2):331-48 [16580915.001]
  • [Cites] Pathol Oncol Res. 2006;12(2):87-91 [16799709.001]
  • [Cites] Oral Oncol. 2007 Feb;43(2):193-8 [16854613.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):224-31 [16931119.001]
  • [Cites] Cell. 2007 Jul 13;130(1):51-62 [17632056.001]
  • [Cites] J Oral Pathol Med. 2008 Mar;37(3):127-33 [18251935.001]
  • [Cites] Cell Cycle. 2008 Mar 1;7(5):592-6 [18256542.001]
  • [Cites] Trends Mol Med. 2008 Apr;14(4):152-60 [18329957.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3722-8 [18559589.001]
  • [Cites] MMWR Surveill Summ. 2008 Sep 5;57(8):1-33 [18772853.001]
  • [Cites] Head Neck Oncol. 2009;1:5 [19284694.001]
  • [Cites] J Natl Cancer Inst. 2009 Jun 3;101(11):793-805 [19470954.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5092-100 [19671842.001]
  • [CommentOn] Cancer Biol Ther. 2010 Oct 1;10(7):700-2 [20729627.001]
  • (PMID = 21068540.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R21 AI047859; United States / NIDCR NIH HHS / DE / K99DE018191; United States / NIDCR NIH HHS / DE / R00 DE018191; United States / NIDCR NIH HHS / DE / K99 DE018191; United States / NIAID NIH HHS / AI / AI47859; United States / NIDCR NIH HHS / DE / T32 DE007200; United States / NIAID NIH HHS / AI / R01 AI047859
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / KIAA1524 protein, human; 0 / Membrane Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC3230513
  •  go-up   go-down


49. Siddiqui F, Patel M, Khan M, McLean S, Dragovic J, Jin JY, Movsas B, Ryu S: Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1047-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region.
  • METHODS AND MATERIALS: Patients with pathologically proven malignant lesions in the head-and-neck region were treated using single-dose SBRT (S-SBRT) or fractionated SBRT (F-SBRT).
  • There were three groups of patients: those with primary (n = 10), recurrent (n = 21), and metastatic tumors (n = 13).
  • The predominant histologic type was squamous cell carcinoma (n = 33).
  • Tumor control rates at 1 year were 83.3% and 60.6% in the primary and recurrent groups, respectively.
  • Median overall survival was 28.7, 6.7, and 5.6 months for the primary, recurrent, and metastatic groups, respectively.
  • CONCLUSIONS: The SBRT in single or fractionated doses offers a viable treatment option for selected patients with primary, recurrent, and metastatic head-and-neck cancers with functional preservation.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327895.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Buscarini M, Quek ML, Gilliam-Hegarich S, Kasahara N, Bochner B: Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. Urol Int; 2007;78(2):160-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder.
  • OBJECTIVE: The insertion of absent or underexpressed genes into cancer cells to alter their malignant phenotype is an important potential application of available gene therapy technology.
  • Adenoviral infection of cells is mediated through a complex pathway, initiated following viral-cell attachment.
  • Adenoviral-cell attachment occurs following interactions with a 46-kDa transmembrane protein with high affinity for both the Coxsackie and adenovirus, designated the CAR (Coxsackie and adenoviral receptor).
  • Additional important cell-viral interactions that occur involve the alpha(v)-based integrins, specifically alpha(v)beta3 and alpha(v)beta5.
  • MATERIAL AND METHODS: Frozen tissue samples of normal bladder and invasive transitional cell cancers of the bladder were evaluated.
  • Tissue blocks containing muscle-invasive transitional cell carcinoma (TCC) were obtained following radical cystectomy, which were performed at our institution.
  • Thirty-two invasive transitional cell bladder tumors were evaluated, each with a matched sample of histologically normal-appearing bladder used as a control.
  • Bladder transitional cell carcinoma: CAR immunoreactivity against TCC cells was uniformly decreased compared to normal transitional cells.
  • In some cases, the absence of CAR positivity was associated with histological evidence of carcinoma in situ.
  • In 6 cases, it led to the identification of small regions of carcinoma in situ that were not noted on primary pathological evaluation.
  • Transitional cell cancers demonstrated a similar pattern of expression of alpha(v)beta5, in which all tumor cells exhibited minimal or no staining.
  • CONCLUSIONS: The success of all viral-mediated gene therapy strategies relies on the ability of the vector to efficiently deliver its genetic material to a target cell population.
  • Deeper layers of the epithelium also express CAR, including the basal layer cells.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Integrin alphaVbeta3 / biosynthesis. Integrins / biosynthesis. Receptors, Virus / biosynthesis. Receptors, Vitronectin / biosynthesis. Urinary Bladder / metabolism. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17293658.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CLMP protein, human; 0 / CLMP protein, mouse; 0 / Coxsackie and Adenovirus Receptor-Like Membrane Protein; 0 / Integrin alphaVbeta3; 0 / Integrins; 0 / Receptors, Virus; 0 / Receptors, Vitronectin; 0 / integrin alphaVbeta5
  •  go-up   go-down


51. Rass K, Tilgen W: Treatment of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol; 2008;624:296-318
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanoma survival mainly depends on primary tumor thickness underlining the importance of primary and secondary prevention by avoidance or early detection of the disease.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Melanoma / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348465.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 118
  •  go-up   go-down


52. Punjabi S, Cook LJ, Kersey P, Marks R, Cerio R: Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study. Int J Dermatol; 2008 Jan;47(1):78-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study.
  • OBJECTIVE: To assess the safety and efficacy of a 0.005% mixture of solasodine glycosides (Zycure) in the treatment of basal cell carcinoma.
  • MAIN OUTCOME MEASURES: The primary efficacy endpoint was histologically confirmed clearance of the basal cell carcinoma (2-mm punch biopsy) at the end of 8-week treatment.
  • CONCLUSION: We conclude that the solasodine glycoside cream Zycure is a safe therapy for basal cell carcinoma, with a cure rate of 66% at 8 weeks and 78% at 1 year follow-up.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Glycosides / administration & dosage. Skin Neoplasms / drug therapy. Solanaceous Alkaloids / administration & dosage
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Double-Blind Method. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Occlusive Dressings. Patient Dropouts. Pharmaceutical Vehicles / adverse effects. Pharmaceutical Vehicles / chemistry. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. SOLASODINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18173610.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glycosides; 0 / Pharmaceutical Vehicles; 0 / Solanaceous Alkaloids; L40Y453Y96 / solasodine
  •  go-up   go-down


53. Hassanpour SE, Kalantar-Hormozi A, Motamed S, Moosavizadeh SM, Shahverdiani R: Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients. Ann Plast Surg; 2006 Nov;57(5):509-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common human malignant neoplasm.
  • We compared these 2 groups in 16 different parameters, which included general information (age, sex), disease history (time interval from onset of lesion to the first office visit, number of admissions, total length of hospital stay), tumor specifications (number of primary lesions, invasion depth, histologic subtypes, location), surgical history (number of operations in our center and other hospitals, type of surgical treatment, margins of resection), recurrences, new lesions, and metastasis.
  • Mean number of primary lesions, the location of tumor, and the depth of invasion did not differ significantly between the 2 groups (P = 0.34, P = 0.78, and P = 0.73, respectively).
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Basal Cell / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / radiotherapy. Skin Neoplasms / surgery. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Plast Surg. 2007 May;58(5):589; author reply 589-90 [17452854.001]
  • (PMID = 17060730.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Mabruk MJ, Toh LK, Murphy M, Leader M, Kay E, Murphy GM: Investigation of the effect of UV irradiation on DNA damage: comparison between skin cancer patients and normal volunteers. J Cutan Pathol; 2009 Jul;36(7):760-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to sunlight is the primary etiological agent for basal cell carcinoma (BCC).
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. DNA Damage / radiation effects. Pyrimidine Dimers / metabolism. Skin Neoplasms / metabolism. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons A/S.
  • (PMID = 19519607.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Pyrimidine Dimers
  •  go-up   go-down


55. Mitsuhashi T, Itoh T, Shimizu Y, Ban S, Ogawa F, Hirose T, Shimizu M: Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants. J Cutan Pathol; 2006 Mar;33(3):246-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants.
  • Basosquamous carcinoma (BSC) is defined as a tumor containing the areas of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) with a transition zone linking the two.
  • Spindle cell squamous carcinoma (SCSC) may have a variable component of conventional SCC and spindle cells.
  • Immunohistochemically, the tumor cells in the SCSC (both conventional and spindle cell) area co-expressed CAM5.2, and vimentin.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466514.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Lal DR, Clark I, Shalkow J, Downey RJ, Shorter NA, Klimstra DS, La Quaglia MP: Primary epithelial lung malignancies in the pediatric population. Pediatr Blood Cancer; 2005 Oct 15;45(5):683-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary epithelial lung malignancies in the pediatric population.
  • BACKGROUND: Primary epithelial lung malignancies are rare in childhood and adolescence.
  • We reviewed the Memorial Sloan-Kettering Cancer Center experience with these tumors to better understand their histology, time to diagnosis, treatment, and outcome.
  • PROCEDURE: A retrospective review was performed on all patients 21 years of age or younger at diagnosis, treated for primary epithelial lung malignancies at Memorial Sloan-Kettering Cancer Center between 1980 and 2001.
  • RESULTS: We identified 11 patients with primary epithelial lung malignancy.
  • The median age at diagnosis was 19 (range: 12-21) years.
  • Seven patients (64%) were initially diagnosed as having pneumonia which contributed to a delay in diagnosis.
  • Final pathologic diagnoses included adenocarcinoma (four), carcinoid tumor (three typical, one atypical), basaloid carcinoma (two), and mucoepidermoid carcinoma (one).
  • CONCLUSIONS: When children and adolescents present with primary epithelial lung malignancy a majority will have advanced disease and experience a delay in diagnosis.
  • Carcinoid tumors are more frequent, and less common subtypes of bronchogenic carcinoma are also more prevalent in the pediatric age group.
  • The highly aggressive basaloid carcinoma has the worst.
  • [MeSH-major] Carcinoma / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adolescent. Adult. Carcinoid Tumor / diagnosis. Carcinoid Tumor / pathology. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Child. Diagnostic Errors. Female. Humans. Male. Pneumonia / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714450.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Puri PK, Galan A, Glusac EJ, Cowper SE: Metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm. J Cutan Pathol; 2008 Jan;35(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm.
  • OBJECTIVE: Metastatic cutaneous neoplasms may be difficult to differentiate from primary cutaneous neoplasms.
  • Herein, we report an unusual case of metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm.
  • METHODS: A 53-year-old male man presented with a neoplasm on the vertex of the scalp, clinically resembling a pigmented basal cell carcinoma.
  • RESULTS: A shave biopsy was suggestive of an apocrine poroma, however, a metastatic carcinoma could not be excluded.
  • After acquiring additional clinical information and the complete excision of the neoplasm, further immunohistochemical stains supported the diagnosis a metastatic carcinoid tumor.
  • CONCLUSION: To our knowledge, this is the first case of metastatic carcinoid tumor reported that has mimicked a poroid neoplasm.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Apocrine Glands / pathology. Carcinoid Tumor / diagnosis. Skin Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095995.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


58. Miliauskas JR, Hunt JL: Primary unilateral multifocal pleomorphic adenoma of the parotid gland: molecular assessment and literature review. Head Neck Pathol; 2008 Dec;2(4):339-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary unilateral multifocal pleomorphic adenoma of the parotid gland: molecular assessment and literature review.
  • Tumors that can be multicentric include Warthin tumor, oncocytoma, basal cell adenoma and acinic cell carcinoma.
  • The incidence of multiple primary unilateral pleomorphic adenomas is extremely rare in patients with no prior history of trauma or surgery.
  • We report two cases of primary multicentric pleomorphic adenoma and review the literature.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Loss of Heterozygosity. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Aged. Clone Cells. DNA, Neoplasm / analysis. Female. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngorhinootologie. 2007 Jun;86(6):448-50 [17219338.001]
  • [Cites] Lab Invest. 2001 Sep;81(9):1289-97 [11555676.001]
  • [Cites] Ear Nose Throat J. 2002 May;81(5):341-5 [12025006.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Sep;33(6):531-4 [15308250.001]
  • [Cites] Arch Otolaryngol. 1966 Sep;84(3):329-31 [4287765.001]
  • [Cites] Am J Surg. 1969 Nov;118(5):787-9 [4310431.001]
  • [Cites] J Laryngol Otol. 1977 Jul;91(7):629-32 [197179.001]
  • [Cites] Laryngoscope. 1982 Nov;92(11):1265-8 [6292599.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1219-24 [2917323.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):431-5 [8630948.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jan;32B(1):3-7 [8729611.001]
  • [Cites] Cancer. 1953 Nov;6(6):1065-133 [13106826.001]
  • [Cites] Ann Otolaryngol. 1954;71(5-6):474-5 [13181211.001]
  • [Cites] Acta Otolaryngol Suppl. 1964;188:SUPPL 191:1-99 [14156485.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):498-503 [10821498.001]
  • (PMID = 20614306.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2807582
  • [Keywords] NOTNLM ; Multifocal / Parotid gland / Pleomorphic adenoma
  •  go-up   go-down


59. Nur S, Chuang L, Ramaswamy G: Immunohistochemical characterization of cancer antigen in uterine cancers. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1903-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pattern of cancer antigen (CA-125) expression by immunohistochemistry (IHC) was investigated in malignant and nonneoplastic endometrium in endometrial carcinoma.
  • Ninety cases of primary uterine carcinomas (65 endometrioid [EM] carcinoma, 15 serous papillary [SP] carcinoma, 6 carcinosarcomas [malignant mixed müllerian tumors], and 4 clear cell carcinoma [CC]) and adjacent atrophic and/or hyperplastic endometrium were analyzed by IHC for CA-125 expression.
  • The percentage and intensity of luminal, apical, basal, and diffuse cytoplasmic immunostaining of epithelial cells were categorized on a scale of 0-4.
  • The immunoreaction score (IRS score) was calculated and correlated with the grade and stage of carcinoma according to the histologic type.
  • CA-125 expression (3-4/4) was localized in apical borders of grade 1 and grade 2 EM carcinoma and was weak or negative (0-1/4) in grade 3 EM.
  • SP carcinoma and endometrial intraepithelial carcinoma showed much higher mean IRS score than EM.
  • In malignant mixed müllerian tumors (MMMT), the epithelial component stained as above according to the type of epithelial cell differentiation of the neoplastic cells.
  • Benign proliferative glands showed moderate apical luminal, basal, and cytoplasmic staining.
  • IRS score correlated with the grade but not with the stage of EM carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009990.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


60. Jaber K, Hammami H, Youssef S, Robbana F, Dhaoui MR, Doss N: Asynchronous hepatocarcinoma, basal cell carcinoma and ungueal melanoma. Eur J Dermatol; 2009 May-Jun;19(3):260-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asynchronous hepatocarcinoma, basal cell carcinoma and ungueal melanoma.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Hepatocellular / diagnosis. Facial Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Melanoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213653.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


61. Busam KJ, Halpern A, Marghoob AA: Malignant melanoma metastatic to a basal cell carcinoma simulating the pattern of a basomelanocytic tumor. Am J Surg Pathol; 2006 Jan;30(1):133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma metastatic to a basal cell carcinoma simulating the pattern of a basomelanocytic tumor.
  • We report a case of metastatic melanoma colliding with and colonizing a basal cell carcinoma (BCC) on the head of a 69-year-old man.
  • The man had a prior history of multiple primary BCCs and melanomas.
  • One of his primary melanomas, on the left scalp, recurred locally and resulted in the development of numerous in-transit metastases.
  • The intimate association of melanoma cells within the nodules of BCC simulated the pattern of so-called "malignant basomelanocytic tumor," a recently proposed novel entity.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330954.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Gyurova MS, Stancheva MZ, Arnaudova MN, Yankova RK: Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas. Dermatol Online J; 2006;12(3):25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas.
  • An 82-year-old female with with multiple basal cell carcinomas is presented.
  • We injected intralesional bleomycin to eight new histologically proven basal cell cancers.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Carcinoma, Basal Cell / drug therapy. Neoplasms, Second Primary / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638439.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


63. Chatterjee DN, Mondal A: Small cell neuroendocrine carcinoma of nose and paranasal sinuses: a study of three cases with short review of the literature. Indian J Otolaryngol Head Neck Surg; 2009 Mar;61(1):43-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell neuroendocrine carcinoma of nose and paranasal sinuses: a study of three cases with short review of the literature.
  • Primary small cell neuroendocrine carcinoma (SNEC) of nose and paranasal sinuses is an extremely rare malignant tumour known for its aggressive clinical course, high rate of recurrence and poor prognosis.
  • Due to its rarity, the understanding of pathogenesis of the disease, diagnosis and ideal treatment have been difficult.
  • The origin of the tumour is believed from basal cells of the olfactory mucosa.
  • The present study deals with three cases of SNECs of nose and paranasal sinuses in elderly males, their clinical presentations, CT scan findings, histopathological diagnosis with short review of literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Oct 15;54(8):1645-61 [6089995.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2388-405 [7139532.001]
  • [Cites] Ultrastruct Pathol. 1995 Sep-Oct;19(5):347-63 [7483011.001]
  • [Cites] Cancer. 1997 May 1;79(9):1729-36 [9128989.001]
  • [Cites] Hum Pathol. 1998 Aug;29(8):826-32 [9712424.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1617-22 [11037813.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2001 Jan;110(1):76-82 [11201814.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):264-78 [11904342.001]
  • [Cites] J Laryngol Otol. 1965 Mar;79:253-5 [14270662.001]
  • [Cites] J Laryngol Otol. 2006 Apr;120(4):289-97 [16526967.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):775-8 [10782795.001]
  • [Cites] Cancer. 2002 May 15;94(10):2623-34 [12173330.001]
  • (PMID = 23120603.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450128
  • [Keywords] NOTNLM ; Nose / Paranasal sinuses / Small cell neuroendocrine carcinoma
  •  go-up   go-down


64. Youssef AH, Zanetto U, Kaur MR, Chan SY: Granulocytic sarcoma (leukaemia cutis) in association with basal cell carcinoma. Br J Dermatol; 2006 Jan;154(1):201-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma (leukaemia cutis) in association with basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasms, Multiple Primary / pathology. Sarcoma, Myeloid / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403127.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


65. Bouez C, Reynaud C, Noblesse E, Thépot A, Gleyzal C, Kanitakis J, Perrier E, Damour O, Sommer P: The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Clin Cancer Res; 2006 Mar 1;12(5):1463-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model.
  • The aim of this work was to shed light on LOX functions within the epidermis by studying its expression in human basal and squamous cell carcinomas and analyzing the effect of its enzymatic activity inhibition and protein absence on human keratinocytes behavior in a skin equivalent.
  • Lysyl oxidase activity inhibition using beta-aminoproprionitrile in a skin equivalent model prepared with both primary human keratinocytes and HaCaT cell line affected keratin 10 and filaggrin expression and disorganized the collagen network and the basement membrane.
  • Modelization of the invasive phenotype was only noticed in the skin equivalent developed with LOX antisense HaCaT cell line, where the protein LOX is specifically absent.
  • [MeSH-major] Carcinoma, Basal Cell / enzymology. Carcinoma, Squamous Cell / enzymology. Dermis / enzymology. Keratinocytes / enzymology. Models, Biological. Protein-Lysine 6-Oxidase / metabolism. Skin Neoplasms / enzymology
  • [MeSH-minor] Aminopropionitrile / pharmacology. Cells, Cultured. Collagen / metabolism. Fibroblasts / enzymology. Humans. Intermediate Filament Proteins / metabolism. Keratin-10. Keratins / metabolism. Neoplasm Invasiveness. Phenotype

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BETA-AMINOPROPIONITRILE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533769.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / KRT10 protein, human; 0 / filaggrin; 147785-83-9 / Keratin-10; 151-18-8 / Aminopropionitrile; 68238-35-7 / Keratins; 9007-34-5 / Collagen; EC 1.4.3.13 / Protein-Lysine 6-Oxidase
  •  go-up   go-down


66. Martorell-Calatayud A, Requena-Caballero C, Botella-Estrada R, Almenar-Medina S, Sanmartín-Jiménez O, Llombart-Cussac B, Nagore-Enguídanos E, Serra-Guillén C, Echeverría-García B, Guillén-Barona C: [Microcystic adnexal carcinoma: Mohs micrographic surgery as the treatment of choice]. Actas Dermosifiliogr; 2009 Oct;100(8):693-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microcystic adnexal carcinoma: Mohs micrographic surgery as the treatment of choice].
  • [Transliterated title] Carcinoma anexial microquístico: la cirugía micrográfica de Mohs como tratamiento de elección.
  • INTRODUCTION AND OBJECTIVES: Microcystic adnexal carcinoma is a rare and aggressive tumor that manifests clinically as a subcutaneous nodule located on the head or neck.
  • The tumor can be confused clinically and histologically with other benign and malignant skin lesions, often leading to inappropriate initial treatment.
  • The chief concern with microcystic adnexal carcinoma is the elevated morbidity and the high rate of recurrence after wide local excision.
  • MATERIAL AND METHODS: We reviewed the medical histories of 6 consecutive patients with microcystic adnexal carcinoma who underwent Mohs micrographic surgery in our dermatology department between 1995 and 2007.
  • RESULTS: In all cases, lesions were located on the head and were primary tumors.
  • Seventy percent of the tumors were wrongly diagnosed initially as basal cell carcinoma.
  • CONCLUSIONS: The absence of perineural involvement and substantial cell atypia can be attributed to the lesions being primary tumors.
  • This would provide a rationale for definitive radical treatment of the primary tumor from the outset to avoid the complications associated with recurrence.
  • The site and the absence of recurrence in all our patients who underwent Mohs micrographic surgery support the use of this technique as the treatment of choice in microcystic adnexal carcinoma.
  • [MeSH-major] Carcinoma / surgery. Facial Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775547.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


67. Wetzig T, Woitek M, Eichhorn K, Simon JC, Paasch U: Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up. Dermatology; 2010;220(4):363-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up.
  • BACKGROUND: The incidence of skin cancer and especially basal cell carcinoma (BCC) has increased in the last few decades.
  • METHODS: A retrospective analysis of 671 patients (45.3% male, 54.7% female) with 777 primary and 85 with recurrent BCC were collected during 2001-2003.
  • In the group with primary BCC (n = 562), 3 tumor recurrences (0.5%) were identified; in the group with recurrent BCC (n = 68), 2 tumor recurrences (2.9%) were seen, resulting in an overall 5-year recurrence rate of 0.8% for all patients with BCC.
  • CONCLUSION: Local complete tumor resection confirmed by complete margin control using paraffin-embedded sections can achieve excellent cure rates for both primary and recurrent BCC.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Microsurgery / methods. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mohs Surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20484877.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


68. Shapley M: Ten years of skin malignancies in a single general practice. Dermatology; 2005;210(1):15-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recurrence rates for basal cell carcinomas managed in primary care were comparable to rates published for secondary care.
  • CONCLUSION: Almost half of all skin malignancies were wholly managed within primary care.
  • [MeSH-major] Family Practice / standards. Neoplasm Recurrence, Local / epidemiology. Outcome Assessment (Health Care). Skin Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Cohort Studies. England / epidemiology. Female. Humans. Male. Medical Records. Melanoma / epidemiology. Melanoma / etiology. Melanoma / pathology. Middle Aged. Retrospective Studies. State Medicine / standards. State Medicine / utilization

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15604538.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


69. Naumann IC, Cordes SR: Giant basal cell carcinoma of the forehead with extensive intracranial involvement. Ann Otol Rhinol Laryngol; 2007 Sep;116(9):663-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma of the forehead with extensive intracranial involvement.
  • Basal cell carcinoma (BCC) is the most common malignant skin lesion and is frequently curatively treated with local excision.
  • Despite its fairly benign growth pattern, BCC should never be underestimated, and care should be taken not only in the complete primary excision but also in cancer surveillance.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Forehead. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures / methods. Reconstructive Surgical Procedures / methods. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926588.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Adamski H, Le Lan J, Chevrier S, Cribier B, Watier E, Chevrant-Breton J: Primary cutaneous cribriform carcinoma: a rare apocrine tumour. J Cutan Pathol; 2005 Sep;32(8):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform carcinoma: a rare apocrine tumour.
  • BACKGROUND: Primary cutaneous cribriform carcinoma (PCCC) is a rare apocrine tumour occurring in middle-aged people.
  • This neoplasm is often located on the limbs.
  • The histopathological diagnosis is difficult, mainly because this tumour is exceptional.
  • Differential diagnoses, including cutaneous metastasis of adenocarcinoma, adenoid basal cell carcinoma and adenoid cystic carcinoma, are discussed.
  • [MeSH-minor] Adult. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115058.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


71. Braun-Falco M: Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type. J Cutan Pathol; 2007 Sep;34(9):731-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type.
  • BACKGROUND: The combination of malignant melanoma (MM) and basal cell carcinoma (BCC) within a single tumor is an unusual finding.
  • CONCLUSION: By reviewing the low number of published cases, we found that a combined MM-BCC tumor exists in two variants: a collision type in which components of each cell type are clearly demarcated and an intermingled type in which both cell types grow intimately together.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696923.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


72. Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ, Husseinzadeh N, Witte DP, Wikenheiser-Brokamp KA, Lambert PF, Wells SI: DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol; 2009 Jan;174(1):71-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show here that DEK overexpression disrupts the normal differentiation program in a manner that is independent of either p53 or cell death.
  • DEK expression was distinctly repressed upon the differentiation of cultured primary human keratinocytes, and stable DEK overexpression caused epidermal thickening in an organotypic raft model system.
  • The observed hyperplasia involved a delay in keratinocyte differentiation toward a more undifferentiated state, and expansion of the basal cell compartment was due to increased proliferation, but not apoptosis.
  • In further support of bona fide oncogenic DEK activities, we report here up-regulated DEK protein levels in both human papilloma virus-positive hyperplastic murine skin and a subset of human squamous cell carcinomas.
  • We suggest that DEK up-regulation may contribute to carcinoma development at least in part through increased proliferation and retardation of differentiation.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1308-12 [10837023.001]
  • [Cites] Trends Biochem Sci. 2000 Mar;25(3):112-4 [10694879.001]
  • [Cites] J Cell Biol. 2000 Jul 24;150(2):309-20 [10908574.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):535-46 [11058868.001]
  • [Cites] Genes Dev. 2001 Feb 15;15(4):398-403 [11230148.001]
  • [Cites] Hum Pathol. 2001 May;32(5):479-86 [11381365.001]
  • [Cites] Gene Ther. 2001 May;8(10):811-7 [11420646.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25804-12 [11320078.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):26317-23 [11333257.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4987-97 [11532962.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):524-8 [12051885.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):24988-94 [11997399.001]
  • [Cites] J Cell Sci. 2002 Aug 15;115(Pt 16):3319-30 [12140263.001]
  • [Cites] J Virol. 2003 Mar;77(5):2832-42 [12584306.001]
  • [Cites] Nucleic Acids Res. 2003 Mar 1;31(5):1571-5 [12595566.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 1;31(23):7003-10 [14627833.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):476-85 [14675665.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1935-41 [14738146.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3536-51 [15060172.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):6000-10 [15199153.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):6011-20 [15199154.001]
  • [Cites] Protein Sci. 2004 Aug;13(8):2252-9 [15238633.001]
  • [Cites] Curr Opin Urol. 2004 Sep;14(5):277-86 [15300148.001]
  • [Cites] Mol Cancer Res. 2007 Sep;5(9):881-90 [17855657.001]
  • [Cites] Mol Cell Biol. 2008 May;28(10):3245-57 [18332104.001]
  • [Cites] Oncogene. 2008 May 1;27(20):2843-50 [18037962.001]
  • [Cites] Pathol Int. 2008 Jun;58(6):378-82 [18477217.001]
  • [Cites] Baillieres Clin Haematol. 1992 Oct;5(4):857-79 [1308167.001]
  • [Cites] J Dermatol Sci. 1994 Dec;8(3):171-7 [7865473.001]
  • [Cites] J Virol. 1996 Mar;70(3):1873-81 [8627712.001]
  • [Cites] J Virol. 1997 Jul;71(7):5161-72 [9188583.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4990-6 [10519413.001]
  • [Cites] Gene. 2004 Dec 8;343(1):1-9 [15563827.001]
  • [Cites] World J Gastroenterol. 2005 Jul 7;11(25):3850-4 [15991281.001]
  • [Cites] Int Immunol. 2005 Jun;17(6):789-96 [15908448.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31760-7 [15987677.001]
  • [Cites] J Virol. 2005 Nov;79(22):14309-17 [16254365.001]
  • [Cites] Methods Mol Med. 2005;119:141-55 [16353335.001]
  • [Cites] FEBS Lett. 2006 May 29;580(13):3217-22 [16696975.001]
  • [Cites] Cell Cycle. 2006 Jun;5(11):1202-7 [16721057.001]
  • [Cites] Science. 2006 Jun 30;312(5782):1961-5 [16809543.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):26802-12 [16829531.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(20):7506-19 [16894028.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3185-97 [17114587.001]
  • [Cites] Oncogene. 2006 Nov 30;25(56):7421-33 [16767161.001]
  • [Cites] J Virol. 2007 Mar;81(5):2102-16 [17182682.001]
  • [Cites] Neoplasia. 2007 Feb;9(2):166-80 [17356713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3255-60 [17360634.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jul;46(7):617-34 [17437278.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 13;358(4):1008-14 [17524367.001]
  • [Cites] Nat Struct Mol Biol. 2007 Jun;14(6):548-55 [17529993.001]
  • [Cites] Eur J Clin Invest. 2007 Aug;37(8):658-64 [17635577.001]
  • [Cites] Oncogene. 2007 Aug 9;26(36):5169-83 [17334395.001]
  • [Cites] Crit Rev Oral Biol Med. 1999;10(4):442-57 [10634582.001]
  • [Cites] J Invest Dermatol. 2000 Mar;114(3):444-55 [10692102.001]
  • [Cites] Cancer Lett. 2000 Aug 11;156(2):191-8 [10880769.001]
  • (PMID = 19036808.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL079193; United States / NCI NIH HHS / CA / R01 CA098428-07; United States / NCI NIH HHS / CA / P01 CA022443-320006; United States / NCI NIH HHS / CA / T32 CA059268; United States / NCI NIH HHS / CA / CA098428; United States / NCI NIH HHS / CA / R01 CA102357; United States / NCI NIH HHS / CA / CA022443-320006; United States / NHLBI NIH HHS / HL / R01 HL079193; United States / NCI NIH HHS / CA / T32 CA59268; United States / NCI NIH HHS / CA / CA102357; United States / NCI NIH HHS / CA / P01 CA022443-310006; United States / NCI NIH HHS / CA / CA116316; United States / NCI NIH HHS / CA / CA022443-310006; United States / NCI NIH HHS / CA / R01 CA098428-06; United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / R01 CA116316; United States / NCI NIH HHS / CA / R01 CA098428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Dek protein, human; 0 / Membrane Proteins; 0 / Oncogene Proteins; 0 / PDRG1 protein, human; 0 / Papillomavirus E7 Proteins
  • [Other-IDs] NLM/ PMC2631320
  •  go-up   go-down


73. Østergaard J, Boberg-Ans J, Prause JU, Heegaard S: Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva. Graefes Arch Clin Exp Ophthalmol; 2005 Jun;243(6):615-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva.
  • BACKGROUND: To report the clinical and histopathological characteristics of a patient with a primary basal cell carcinoma (BCC) of the caruncle with seeding of the tumour to the conjunctiva.
  • Microscopically, both neoplasms were composed of infiltrative islands of basaloid tumour cells, scattered mitoses and peripheral palisading consistent with the diagnosis of BCC.
  • CONCLUSION: This case describes a primary BCC of the caruncle with seeding to the conjunctiva.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Conjunctival Neoplasms / secondary. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eye Neoplasms / pathology. Eye Neoplasms / surgery. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Tears.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surv Ophthalmol. 1993 Sep-Oct;38(2):169-92 [8235999.001]
  • [Cites] Arch Ophthalmol. 1998 Oct;116(10):1373-4 [9790642.001]
  • [Cites] Arch Ophthalmol. 2000 Sep;118(9):1296-8 [10980780.001]
  • [Cites] Br J Ophthalmol. 1973 Nov;57(11):836-7 [4785248.001]
  • [Cites] Am J Ophthalmol. 1982 Nov;94(5):591-3 [7148940.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1720-2 [8233401.001]
  • [Cites] Cornea. 1987;6(2):78-116 [3301209.001]
  • [Cites] Indian J Ophthalmol. 1975 Oct;23(3):33-4 [1236314.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Oct;78(5):547-52 [11037913.001]
  • [Cites] Arch Ophthalmol. 1997 Dec;115(12):1585-7 [9400796.001]
  • (PMID = 15614536.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Bøgelund FS, Philipsen PA, Gniadecki R: Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol; 2007;87(4):330-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting the recurrence rate of basal cell carcinoma.
  • The aim of this retrospective survey was to determine recurrence rates after treatment of basal cell carcinomas in a single academic dermatology department.
  • A total of 1016 patients with 1593 histologically verified basal cell carcinomas (n=1212 primary and n=381 relapsing) were included.
  • The relapse rate for primary basal cell carcinomas on the scalp was highest (odds ratio (OR)=2.8, 95% confidence interval (CI) 1.5-5.3).
  • T2 and T3 tumours showed a 2- and 3-fold increased relapse rate, respectively, compared with T1 basal cell carcinomas.
  • Recurrent basal cell carcinomas had a higher relapse rate than primary lesions (OR=1.8, CI=1.4-2.2).
  • Thus, in an uncontrolled, real-life situation curettage or photodynamic therapy are associated with significantly higher relapse risk than excision and radiotherapy and therefore should not be used for high risk primary tumours or recurrent tumours.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598036.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


75. Stang A, Ziegler S, Büchner U, Ziegler B, Jöckel KH, Ziegler V: Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: a patient- vs. diagnosis-based incidence approach. Int J Dermatol; 2007 Jun;46(6):564-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: a patient- vs. diagnosis-based incidence approach.
  • The aims of this study were to estimate the patient incidence rates of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and skin melanoma, and to study the effect of multiple primary skin tumors on the incidence rates.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Neoplasms, Multiple Primary / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550552.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Heal C, Raasch B: Diagnosing skin cancer in primary care: how do main-stream general practitioners compare with primary care skin cancer clinic doctors? Med J Aust; 2008 Jan 21;188(2):125; author reply 126
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing skin cancer in primary care: how do main-stream general practitioners compare with primary care skin cancer clinic doctors?
  • [MeSH-major] Ambulatory Care Facilities. Physicians, Family. Primary Health Care. Skin Neoplasms / diagnosis
  • [MeSH-minor] Australia. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnosis-Related Groups. Humans. Physical Examination

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Med J Aust. 2007 Aug 20;187(4):215-20 [17708723.001]
  • (PMID = 18205594.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Letter
  • [Publication-country] Australia
  •  go-up   go-down


77. Malik V, Goh KS, Leong S, Tan A, Downey D, O'Donovan D: Risk and outcome analysis of 1832 consecutively excised basal cell carcinomas in a tertiary referral plastic surgery unit. J Plast Reconstr Aesthet Surg; 2010 Dec;63(12):2057-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk and outcome analysis of 1832 consecutively excised basal cell carcinomas in a tertiary referral plastic surgery unit.
  • BACKGROUND: Basal cell carcinomas are the most prevalent of all skin cancers worldwide and form the majority of the surgical workload for most modern cutaneous malignancy centres.
  • Primary surgical removal of basal cell carcinomas remains the gold standard of treatment but, despite almost two centuries of surgical experience, rates of incomplete surgical excision of up to 50% are still reported.
  • The aim of this study was to assess, quantify and perform comparative analysis of the outcomes and predictive factors of consecutive primarily-excised basal cell carcinomas in a tertiary centre over a six-year period.
  • METHODS: Retrospective audit was conducted on all patients who underwent surgical excision of basal cell carcinomas from January 2000 to December 2005.
  • RESULTS: One thousand eight hundred and thirty two basal cell carcinomas were excised from 1329 patients over the designated time period.
  • CONCLUSIONS: Overall basal cell carcinomas excision rates compared favourably with international reported standards but attention to a variety of surgical and histological risk factors may improve this further.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20226750.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


78. Wheeler T: The role of skin assessment in older people. Br J Community Nurs; 2009 Sep;14(9):380-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin health checks should become a normal part of health surveillance in primary care.
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / prevention & control. Emollients / therapeutic use. Humans. Skin Diseases / epidemiology. Skin Diseases / prevention & control. Skin Neoplasms / epidemiology. Skin Neoplasms / prevention & control. Sunscreening Agents / administration & dosage. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19749656.001).
  • [ISSN] 1462-4753
  • [Journal-full-title] British journal of community nursing
  • [ISO-abbreviation] Br J Community Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Emollients; 0 / Sunscreening Agents
  •  go-up   go-down


79. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S, Basolo F, Orlando C, Miccoli P: Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer; 2009 Dec;16(4):1299-311
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combined effects of interferon gamma (IFNgamma) and tumor necrosis factor alpha (TNFalpha) stimulation on CXCL10 secretion in primary cells from PTCs and TFC were tested.
  • Furthermore, the effect of PPARgamma activation by TZDs, on CXCL10 secretion and proliferation in these cell types was studied.
  • In primary cultures of TFC and PTCs CXCL10 production was absent under basal conditions; a similar dose-dependent secretion of CXCL10 was induced by IFNgamma in both cell types.
  • The stimulation with IFNgamma+TNFalpha induced a synergistic CXCL10 release in both cell types; however, a secretion more than ten times higher was induced in PTCs.
  • [MeSH-major] Carcinoma, Papillary / drug therapy. Chemokine CXCL10 / metabolism. PPAR gamma / agonists. Thiazolidinediones / pharmacology. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Cell Proliferation / drug effects. Cells, Cultured. Electrophoretic Mobility Shift Assay. Humans. Immunoblotting. Immunoenzyme Techniques. Interferon-gamma / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / drug effects. Thyroid Gland / metabolism. Tumor Necrosis Factor-alpha / pharmacology

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755523.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CXCL10; 0 / PPAR gamma; 0 / RNA, Messenger; 0 / Thiazolidinediones; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


80. Yao M, Smith RB, Hoffman HT, Funk GF, Graham MM, Buatti JM: Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance. Am J Clin Oncol; 2005 Apr;28(2):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare skin neuroendocrine carcinoma frequently occurring in the head and neck area.
  • [MeSH-major] Carcinoma, Merkel Cell / radionuclide imaging. Carcinoma, Merkel Cell / secondary. Lymphatic Metastasis / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / radionuclide imaging. Carcinoma, Basal Cell / secondary. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Fluorodeoxyglucose F18. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radionuclide imaging. Humans. Male. Middle Aged. Neoplasms, Multiple Primary / radionuclide imaging. Radiopharmaceuticals. Skin Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803018.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


81. Gallagher G, Forrest DL: Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer; 2007 Jan 1;109(1):84-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second solid cancers after allogeneic hematopoietic stem cell transplantation.
  • BACKGROUND: The objective of this study was to establish the incidence and risk factors for the development of second solid cancers after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • RESULTS: Twenty-eight patients developed 30 solid malignancies at a median of 6.8 years after allo-HSCT (range, 0.12-17.3 years) for a 10-year cumulative incidence of 3.1% (95% confidence interval [95% CI], 2-5%; all solid tumors) and 2.3% (95% CI 1-4%; excluding basal cell carcinoma and carcinoma in situ).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasms, Second Primary / etiology


82. Spinelli HM, Shapiro MD, Wei LL, Elahi E, Hirmand H: The role of lacrimal intubation in the management of facial trauma and tumor resection. Plast Reconstr Surg; 2005 Jun;115(7):1871-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The literature widely documents several reliable, safe, and consistently well-tolerated techniques of nasolacrimal intubation for the repair of lacrimal system dysfunction; however, the role and the timing of such intubation in primary surgery involving the regional anatomy of the lacrimal system remain controversial.
  • The authors evaluated the role of lacrimal intubation as a therapeutic and prophylactic procedure in complex primary surgery for trauma, tumor, and chronic infection of the lacrimal drainage system.
  • METHODS: Sixty-one cases of either unilateral or bilateral silicone intubation of the lacrimal drainage system in 54 patients were analyzed retrospectively with respect to diagnosis, indication for intubation (therapeutic or prophylactic), and clinical outcome.
  • Final long-term patency of the system after tube removal was assessed by the absence of epiphora and positive Jones primary dye test.
  • RESULTS: Lacrimal intubation as part of the primary repair of facial trauma, tumor resection, and relief of lacrimal system obstruction resulted in a patent, functional lacrimal drainage system in all 61 cases, with no associated morbidity.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Dacryocystorhinostomy. Eye Neoplasms / surgery. Facial Injuries / surgery. Facial Neoplasms / surgery. Lacrimal Apparatus Diseases / surgery


83. Ronen O, Malone JP, Kay P, Bivens C, Hall K, Paruchuri LP, Mo YY, Robbins KT, Ran S: Expression of a novel marker, Ubc9, in squamous cell carcinoma of the head and neck. Head Neck; 2009 Jul;31(7):845-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a novel marker, Ubc9, in squamous cell carcinoma of the head and neck.
  • The objective of this study was to determine the expression of Ubc9 in squamous cell carcinoma of the head and neck (SCCHN).
  • Ubc9 was significantly upregulated in the malignant and peritumoral tissues compared with mucosa from normal individuals.
  • In peritumoral tissues, Ubc9 expression was detected in the basal and suprabasal epithelial layers.
  • CONCLUSIONS: Ubc9 is significantly overexpressed in the primary SCCHN tumors and peritumoral mucosa compared with normal epithelial cells.
  • [MeSH-major] Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / enzymology. Head and Neck Neoplasms / pathology. Ubiquitin-Conjugating Enzymes / metabolism
  • [MeSH-minor] Adult. Biomarkers / metabolism. Case-Control Studies. Female. Humans. Male. Middle Aged. Mucous Membrane / enzymology. Mucous Membrane / pathology. Neoplasm Invasiveness. Neoplasm Staging


84. Selicharová I, Smutná K, Sanda M, Ubik K, Matousková E, Bursíková E, Brozová M, Vydra J, Jirácek J: 2-DE analysis of a new human cell line EM-G3 derived from breast cancer progenitor cells and comparison with normal mammary epithelial cells. Proteomics; 2007 May;7(9):1549-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-DE analysis of a new human cell line EM-G3 derived from breast cancer progenitor cells and comparison with normal mammary epithelial cells.
  • We performed a 2-DE analysis of proteins of the newly established spontaneously immortalized clonal cell line EM-G3 derived from a primary lesion of infiltrating ductal breast carcinoma.
  • NME cells are a mixture of both main cell types in breast epithelia, myoepithelial and luminal cells.
  • The EM-G3 breast cancer cell line has a unique basal-like phenotype.
  • Cytokeratin 16, cytokeratin 19, squamous cell carcinoma antigen 1, caphepsin B and caspase 14 were predominantly expressed by NME cells.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Cell Line, Tumor. Mammary Glands, Human / cytology. Neoplasm Proteins / chemistry. Proteome / chemistry. Stem Cells / chemistry


85. Ben Slama L: [Carcinoma of the lips]. Rev Stomatol Chir Maxillofac; 2009 Nov;110(5):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma of the lips].
  • Epidermoid carcinoma, that is, squamous cell carcinoma of the skin, is the most common malignant tumor of the lips.
  • Its primary causes are sun exposure, smoking, and chronic irritation.
  • Epidermoid carcinoma may appear clinically as a scaly erosion or an ulceration.
  • [MeSH-minor] Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Humans. Leukoplakia, Oral / pathology. Smoking / adverse effects. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361830.001).
  • [ISSN] 1776-257X
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 10
  •  go-up   go-down


86. Mhawech-Fauceglia P, Herrmann FR, Bshara W, Odunsi K, Terracciano L, Sauter G, Cheney RT, Groth J, Penetrante R, Mhawech-Fauceglia P: Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol; 2007 Jun;60(6):694-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody.
  • However, it is also expressed in subsets of lymphoblastic lymphoma, Merkel cell carcinoma (MCC) and desmoplastic small round cell tumour (DSRCT).
  • AIM: To determine expression of FLI-1 in various benign and malignant neoplasms, by immunohistochemical analysis on 4323 tumours using multiple tumour microarrays, as well as on whole sections.
  • RESULTS: FLI-1 was expressed in 46/62 EWS/PNETs, 2/3 olfactory neuroblastomas, 7/102 small cell carcinomas of the lung, 10/34 MCCs, 1/14 rhabdomyosarcoma, 19/132 non-Hodgkin's lymphomas, 2/3 DSRCTs, and in 53/74 benign and malignant vascular tumours.
  • In addition, 27/508 squamous cell carcinomas, 19/837 adenocarcinomas, 10/400 urothelial bladder cancers, 1/40 basal cell carcinomas, 3/29 liposarcomas, 1/40 glioblastoma multiforme and 9/29 medullar carcinomas of the breast expressed FLI-1.
  • Finally, the sensitivity and specificity of FLI-1 to distinguish EWS/PNET from other small round cell tumours (SRCTs) were 74.2% and 91.6%, respectively.
  • This finding should be kept in mind, especially when using FLI-1 as a marker for finding the primary origin of poorly differentiated metastatic tumour.
  • [MeSH-minor] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / metabolism. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / metabolism. Protein Array Analysis / methods. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / metabolism. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1061-6 [11474291.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1657-62 [11117787.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5747-54 [11607824.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):320-7 [11859203.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Mod Pathol. 2004 May;17(5):547-52 [15001993.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):160-5 [15354743.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Int J Dev Biol. 1998 May;42(4):561-72 [9694627.001]
  • [Cites] Histopathology. 2005 Jun;46(6):622-34 [15910593.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1025-33 [16006796.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1184-93 [16096408.001]
  • [Cites] Int J Gynecol Pathol. 2006 Apr;25(2):151-4 [16633064.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):216-24 [10968707.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):255-60 [11556754.001]
  • (PMID = 16917000.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Protein c-fli-1
  • [Other-IDs] NLM/ PMC1955051
  •  go-up   go-down


87. Heneghan MK, Hazan C, Halpern AC, Oliveria SA: Skin cancer coverage in a national newspaper: a teachable moment. J Cancer Educ; 2007;22(2):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted an advanced focus search of all "skin cancer" articles using key words "melanoma," "squamous cell carcinoma," "basal cell carcinoma," "sunscreen," "tanning," "sunbathing," and "tanning salon".
  • Melanoma was the primary subject of the 874 articles, with 29% of the articles focusing on some aspect of melanoma.
  • Coverage of other major subjects included sunscreen (11%), tanning (9%), basal cell carcinoma (7%), squamous cell carcinoma (3%), sunbathing (2%), and tanning salon (2%).

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Health Commun. 2000 Apr-Jun;5(2):117-34 [11010345.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jul;62(1):71-9 [10989987.001]
  • [Cites] Am J Public Health. 1989 Nov;79(11):1551-2 [2683815.001]
  • [Cites] AIDS Educ Prev. 1992 Winter;4(4):295-307 [1472415.001]
  • [Cites] Adolescence. 1996 Summer;31(122):253-64 [8726887.001]
  • [Cites] J Am Acad Dermatol. 1986 Apr;14(4):676-9 [3958278.001]
  • [Cites] J Commun. 1975 Summer;25(3):171-3 [1184780.001]
  • [Cites] J Am Acad Dermatol. 1997 Aug;37(2 Pt 1):179-86 [9270501.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):491-6 [15837868.001]
  • [Cites] Addiction. 1997 Jun;92 Suppl 2:S189-99 [9231444.001]
  • [Cites] Prev Med. 2005 Aug;41(2):511-20 [15917047.001]
  • [Cites] Clin Exp Dermatol. 1993 Sep;18(5):396-400 [8252756.001]
  • [Cites] Am J Prev Med. 2004 Jul;27(1):57-65 [15212776.001]
  • [Cites] Health Educ Q. 1996 Aug;23(3):346-64 [8841819.001]
  • [Cites] Public Health Rep. 1982 Mar-Apr;97(2):113-5 [7063590.001]
  • [Cites] J Womens Health Gend Based Med. 2000 Jun;9(5):471-5 [10883937.001]
  • [Cites] J Am Acad Dermatol. 1996 Jun;34(6):971-8 [8647990.001]
  • [Cites] Prev Med. 1992 Sep;21(5):654-69 [1438112.001]
  • [Cites] Arch Intern Med. 1989 Jan;149(1):140-4 [2912403.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1180-3 [1891034.001]
  • [Cites] J Am Diet Assoc. 1977 Nov;71(5):505-9 [615901.001]
  • [Cites] Am J Public Health. 1992 Oct;82(10):1374-6 [1415863.001]
  • [Cites] J Community Health. 1992 Jun;17(3):153-65 [1512306.001]
  • [Cites] J Clin Epidemiol. 1993 Sep;46(9):987-1001 [8263584.001]
  • [Cites] Eval Rev. 1996 Aug;20(4):404-23 [10183257.001]
  • [Cites] Arch Intern Med. 2003 Jul 14;163(13):1601-5 [12860585.001]
  • [Cites] Lancet. 1996 Jun 8;347(9015):1600-3 [8667872.001]
  • [Cites] J Pediatr Psychol. 1994 Feb;19(1):3-17; discussion 19-26 [8151494.001]
  • [Cites] Tob Control. 2003 Sep;12 Suppl 2:ii75-81 [12878777.001]
  • [Cites] J Am Acad Dermatol. 1999 Jul;41(1):81-99 [10411417.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] N Engl J Med. 1998 Jul 9;339(2):87-92 [9654540.001]
  • [Cites] JAMA. 1998 Mar 11;279(10):762-6 [9508152.001]
  • (PMID = 17605623.001).
  • [ISSN] 0885-8195
  • [Journal-full-title] Journal of cancer education : the official journal of the American Association for Cancer Education
  • [ISO-abbreviation] J Cancer Educ
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K07 CA94002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


88. Eng TY, Boersma MG, Fuller CD, Goytia V, Jones WE 3rd, Joyner M, Nguyen DD: A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol; 2007 Dec;30(6):624-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive review of the treatment of Merkel cell carcinoma.
  • Merkel cell carcinoma (MCC) is an uncommon but malignant cutaneous neuroendocrine carcinoma with a high incidence of local recurrence, regional lymph node metastases, and subsequent distant metastases.
  • However, data from recent development support a multimodality approach, including surgical excision of primary tumor with adequate margins and sentinel lymph node dissection followed by postoperative radiotherapy in most cases, as current choice of practice with better locoregional control and disease-free survival.
  • [MeSH-major] Carcinoma, Merkel Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Lymph Node Excision. Lymphatic Metastasis. Prognosis. Sentinel Lymph Node Biopsy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091058.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 206
  •  go-up   go-down


89. Huerva V, Sanchez MC, Egido RM, Matías-Guiu X: Pleomorphic adenoma with extensive myoepithelial component (myoepithelioma) of the lower eyelid. Ophthal Plast Reconstr Surg; 2008 May-Jun;24(3):223-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On presentation to us, the lesion showed a clinical appearance that was very similar to a nodular basal cell carcinoma.
  • A diagnosis of pleomorphic adenoma with extensive myoepithelial component (myoepithelioma) was made.
  • The authors conclude that myoepithelioma should be considered in the differential diagnosis of nodular recurrent masses in the eyelids of adults.
  • Definitive diagnosis is possible only after surgical biopsy.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Eyelid Neoplasms / pathology. Myoepithelioma / pathology. Neoplasm Recurrence, Local. Neoplasms, Multiple Primary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Middle Aged. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520841.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


90. Chen WL, Li JS, Yang ZH, Huang ZQ, Wang JU, Zhang B: Two submental island flaps for reconstructing oral and maxillofacial defects following cancer ablation. J Oral Maxillofac Surg; 2008 Jun;66(6):1145-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary lesions included squamous cell carcinoma of the tongue (8 cases), buccal mucosa (16), floor of the mouth (4), lower gingiva (3), oropharynx (2); recurrent squamous cell carcinoma of the palate (3); and basal cell carcinoma of the facial skin (2).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Face / blood supply. Fatal Outcome. Female. Humans. Male. Middle Aged. Neck / blood supply. Neck / surgery. Neoplasm Staging. Oral Surgical Procedures / methods. Reconstructive Surgical Procedures / methods. Retrospective Studies

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486779.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Marci V, Volante M, Cappia S, Righi L, Novello C, Scagliotti GV, Brambilla E, Papotti M: Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma. Virchows Arch; 2007 Sep;451(3):729-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 2004 WHO classification of lung tumours recognised basaloid carcinoma as a variant of squamous and large cell carcinoma.
  • We report a unique case of primary pulmonary adenocarcinoma with a basaloid component.
  • The patient is disease-free 13 months after diagnosis.
  • Histologically, an invasive carcinoma having a glandular and a solid component was observed.
  • The solid component was an organoid proliferation of basaloid-type cells, as in cutaneous basal cell carcinoma.
  • (1) The solid areas resemble a conventional basaloid carcinoma, except for the presence of small mucin-containing spaces. (2) The mucinous adenocarcinoma areas contain two layers of columnar and basaloid cells. (3) Both components are neoplastic based on cell morphology, invasive properties and phenotypic profile.
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell. Humans. Keratins / analysis. Male. Mucins / analysis. Neoplasm Invasiveness. Phenotype. World Health Organization


92. Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M: The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol; 2008 Jun;87(3):383-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Fifty-nine consecutive patients treated by chemoradiotherapy for anal squamous cell cancer were evaluated for acute and late radiotherapy-related adverse events.
  • In 29 patients, the boost dose to the primary tumour was given by HDR brachytherapy: 30 patients were treated only by external radiotherapy.
  • In patients that received the final boost dose to the primary tumour by HDR brachytherapy, a trend towards lower incidence of radiation proctitis was observed (P=0.065).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Brachytherapy / adverse effects. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiation Injuries. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501454.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


93. Ríos-Martín JJ, González-Cámpora R, Moreno-Ramírez D, Camacho-Martínez F: Sarcomatoid basal cell carcinoma. Am J Dermatopathol; 2005 Dec;27(6):546; author reply 546
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid basal cell carcinoma.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basal Cell / pathology. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Dermatopathol. 2005 Feb;27(1):17-20 [15677971.001]
  • (PMID = 16314711.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


94. Apaydin R, Gürbüz Y, Bayramgürler D, Bilen N: Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study. Amyloid; 2005 Mar;12(1):41-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study.
  • We investigated the expression of CKs immunohistochemically in basal cell carcinomas (BCCs), epidermis overlying tumour, and skin tumor-associated amyloidosis (STA).
  • The primary antibodies of CK1-8 (AE3), CK10 (DEK-10), CK14 (LL002), CK17 (E3), CK18 (DC10), CK19 (KS19.1), CK 5/6/18 (LP34), CK8/18 (5D3) were applied to the section immunohistochemically.
  • [MeSH-major] Amyloidosis / metabolism. Carcinoma, Basal Cell / metabolism. Epidermis / metabolism. Keratins / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076610.001).
  • [ISSN] 1350-6129
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


95. Quigley BC, Ricciuti J, Morgan MB: Amyloid light chain deposition associated with dermatofibroma: serendipity or association? Am J Dermatopathol; 2010 May;32(3):298-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary cutaneous amyloidosis, also known as nodular amyloidosis, is defined as deposition of amyloid light chain in the skin in the absence of a systemic cause of amyloidosis.
  • In contrast, secondary cutaneous amyloidosis is related to lesions such as squamous cell carcinoma, Bowen disease, basal cell carcinoma, and discoid lupus erythematosus, and has been shown in most cases to be derived from keratin epithelial elements.
  • [MeSH-minor] Diagnosis, Differential. Humans. Lipoma / diagnosis. Male. Middle Aged

  • Genetic Alliance. consumer health - Dermatofibroma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110798.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Immunoglobulin Light Chains
  •  go-up   go-down


96. Mc Menamin ME, Goh SG, Poblet E, Gostelow BE, Robson A, Calonje E: Sarcomatoid basal cell carcinoma--predilection for osteosarcomatous differentiation: a series of 11 cases. Am J Surg Pathol; 2006 Oct;30(10):1299-308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid basal cell carcinoma--predilection for osteosarcomatous differentiation: a series of 11 cases.
  • Primary cutaneous carcinomas rarely show heterologous malignant mesenchymal differentiation.
  • We report 11 cases of sarcomatoid basal cell carcinoma (BCC) with osteosarcomatous differentiation.
  • One case showed a purely osteoclastic giant cell rich malignant mesenchyme, interpreted as representing early stages of osteosarcomatous transformation.
  • Previously unreported in sarcomatoid BCC, the mesenchymal component of another two cases displayed predominant malignant giant cell tumor like areas and 1 further case disclosed areas reminiscent of telangiectatic osteosarcoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinosarcoma / pathology. Cell Transformation, Neoplastic / pathology. Osteosarcoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001162.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


97. Spinelli HM, Tabatabai N, Muzaffar AR, Isenberg JS: Upper lip reconstruction with the alar crescent flap: A new approach. J Oral Maxillofac Surg; 2006 Oct;64(10):1566-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant etiologies were responsible for the defect in all patients.
  • Its primary advantage is that it is a single-stage procedure with a relatively low morbidity and patient inconvenience.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / rehabilitation. Cheek / surgery. Facial Muscles / transplantation. Female. Humans. Lip Neoplasms / rehabilitation. Male. Melanoma / rehabilitation. Middle Aged

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982318.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Gordon LG, Scuffham PA, van der Pols JC, McBride P, Williams GM, Green AC: Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings. J Invest Dermatol; 2009 Dec;129(12):2766-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In many developed countries, total costs to health systems for cutaneous basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) are among the highest of all cancers, yet the investment value of preventive measures remains unknown.
  • Using primary data from a randomized controlled trial, we estimated the cost-effectiveness of a skin cancer prevention initiative based on regular sunscreen use.
  • [MeSH-major] Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / prevention & control. Skin Neoplasms / prevention & control. Sunscreening Agents / economics. Sunscreening Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Invest Dermatol. 2009 Dec;129(12):2745-6 [19901945.001]
  • (PMID = 19536149.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


99. Alves R, Ocaña J, Vale E, Correia S, Viana I, Bordalo O: Basal cell carcinoma and atypical fibroxanthoma: an unusual collision tumor. J Am Acad Dermatol; 2010 Sep;63(3):e74-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma and atypical fibroxanthoma: an unusual collision tumor.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology. Xanthomatosis / pathology
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Dermoscopy / methods. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Rare Diseases. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20708468.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


100. Gore SM, Kasper M, Williams T, Regl G, Aberger F, Cerio R, Neill GW, Philpott MP: Neuronal differentiation in basal cell carcinoma: possible relationship to Hedgehog pathway activation? J Pathol; 2009 Sep;219(1):61-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal differentiation in basal cell carcinoma: possible relationship to Hedgehog pathway activation?
  • Although deregulated Hedgehog signalling and elevated Gli transcription factor expression are known to promote the development of basal cell carcinoma (BCC), little is known about molecular mechanisms driving the development of specific growth pattern subtypes.
  • Primary human keratinocytes retrovirally expressing GLI1(-) and GLI2(-) showed elevated levels of beta-tubulin III and ARC but not Neurofilament or GAP-43, suggesting that beta-tubulin III and Arc may be early targets of aberrant Gli expression in BCC, whereas expression of Neurofilament and GAP-43 are either later, downstream targets or under control of alternative pathways.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Gene Expression Regulation, Neoplastic. Hedgehog Proteins / genetics. Neurons / pathology
  • [MeSH-minor] Analysis of Variance. Biomarkers / analysis. Case-Control Studies. Cell Differentiation. Cells, Cultured. Cytoskeletal Proteins / genetics. GAP-43 Protein / genetics. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Keratinocytes / metabolism. Kruppel-Like Transcription Factors / genetics. Nerve Tissue Proteins / genetics. Neurofilament Proteins / genetics. Neuronal Plasticity. Nuclear Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction / physiology. Transcription Factors / genetics. Transduction, Genetic. Tubulin / genetics. Zinc Finger Protein GLI1

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479712.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 20652; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytoskeletal Proteins; 0 / GAP-43 Protein; 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Nerve Tissue Proteins; 0 / Neurofilament Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tubulin; 0 / Zinc Finger Protein GLI1; 0 / activity regulated cytoskeletal-associated protein
  •  go-up   go-down






Advertisement